 
  
 
TPL-000052_v09  
 Macitentan / ACT- 064992  
Portopulmonary hypertension  
AC-055-404 
PORTICO  
A randomized, double -blind, placebo -controlled, prospective, multicenter, parallel 
group study to assess the safety and efficacy of macitentan in patients with 
portopulmonary hypertensi on 
 
 
Study Phase:  4 
ClinicalTrials.gov Identifier  [STUDY_ID_REMOVED] 
Date:  21 April 2016 
Document Version Final Version 3 
Document History : 21 April 2016: Global Amendment 2, resulting in Final  
Version 3 
15 January  2015: Global Amendment 1, resulting in 
Final  Version 2 
05 December 2014: Final Version 1  
 
 
  
 
Confidentiality statement  
Property of Actelion Pharmaceuticals Ltd. May not be used, divulged, published or otherwise disclosed 
without the consent of Actelion Pharmaceuticals Ltd.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 2/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
SPONSOR CONTACT DETAILS 
SPONSOR   
 ACTELION Pharmaceuticals Ltd  
Gewerbestrasse 16  
CH-4123 Allschwil 
Switzerland  
Clinical Trial Physician  
  
  
Fax  
email   
MEDICAL HOTLINE  
 
Toll phone number:    
 
+ 41 61 227 05  63 
  
Site-specific toll telephone numbers and toll -free numbers for the Medical Hotline can 
be found in the Investigator Site File. 
 
 
ACTELION CONTRIBUTORS TO THE PROTOCOL 
Clinical Trial Scientist   
 
Clinical Trial  Statistician   
 
Drug Safety Physician   
 
Clinical Pharmacologist   
 
COORDINATING INVESTIGATOR 
Name / Title  Address  
  
 
 
 
 
 

Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 3/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
CONTRACT RESEARCH ORGANIZATIONS INFORMATION 
 
CENTRAL LABORATORY  
  
 
 
CENTRAL 
RANDOMIZATION  
  
 
 
 
CRO  
  
  
 
 
 
 
 
A list of site -specific contact details for CROs can be found in the Investigator Site File.  
 

Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 4/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
SIGNATURE PAGE FOR ACTELION PHARMACEUTIC ALS LTD  
Hereinafter called Actelion  
 
Treatment name / number Macitentan / ACT -064992 
Indication 
Portopulmonary hypertension 
Protocol number, study acronym, study title  
AC-055-404, PORTICO : A randomized, double -blind, placebo- controlled, prospective, 
multicenter, parallel group study to assess the safety and efficacy of  macitentan in 
patients with portopulmonary hypertension I approve the design of this study.  
 
 

Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 5/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
INVESTIGATOR SIGNATURE PAGE 
Treatment name / number 
Macitentan / ACT -064992 
Indication 
Portopulmonary hypertension Protocol number, study acronym, study title  
AC-055- 404, PORTICO, A randomized, double -blind, placebo- controlled, prospective, 
multicenter, parallel group study to assess the safety and efficacy of macitentan in 
patients with portopulmonary hypertension 
I agree to the terms and conditions relating  to this study as defined in this protocol, the 
electronic Case Report Form (CRF), and any other protocol -related documents. I fully 
understand that any changes instituted by the investigator(s) without previous agreement 
with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other than those procedures necessary for the wellbeing of the subjects).  
I agree to conduct this study in accordance with the Declaration of Helsinki principl es, 
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable regulations and laws. I will obtain approval by an Institutional Review Board or Independent Ethics Committee (IRB/IEC) prior to study start and signed informed consent from all subjects included in this study. If an amendment to the 
protocol is necessary, I will obtain approval by an IRB/IEC and ensure approval by regulatory authorities (if applicable) have been obtained before the implementation of changes described in the amendment. I will allow direct access to source documents and study facilities to sponsor representative(s), particularly monitor(s) and auditor(s), and agree to inspection by regulatory authorities or IRB/IEC representative. I wil l ensure that 
the study treatment(s) supplied by the sponsor are being used only as described in this protocol. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact details and function in an electronic database for internal purposes and for submission to Health Authorities worldwide. 
 Country  Site 
number  Town  Date   Signature  
Site Principal 
Investigator        
 
This center is performing the :  Pharmacokinetic substudy      Hepatic vein catheterization 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 6/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
TABLE OF CONTENTS 
SPONSOR CONTACT DETA ILS ......................................................................................2  
ACTELION CONTRIBUTORS TO THE PROTOCOL  .....................................................2  
COORDINATING INVESTI GATOR .................................................................................2  
CONTRACT RESEARCH  ORGANIZATIONS INFOR MATION  ...................................3  
LIST OF ABBREVIATION S AND ACRONYMS  ..........................................................13  
PROTOCOL SYNOPSIS AC -055-404 .............................................................................17  
1 BACKGROUND  .........................................................................................................29  
1.1 Indication ......................................................................................................29  
1.2 Epidemiology and natural history .................................................................29  
1.3 Current management  .....................................................................................30  
1.4 Endothelin-1 and pulmonary hypertension ...................................................31  
1.5 Macitentan  ....................................................................................................31  
1.5.1  Nonclinical results  ............................................................................31  
1.5.2  Clinical information  ..........................................................................32  
1.5.2.1  Phase 1 studies .........................................................................32  
1.5.2.2  Phase 2 studies .........................................................................33  
1.5.2.3  Phase 3 study in patients with pulmonary arterial 
hypertension ............................................................................34  
1.5.2.4  Summary of potential risks and risk management ..................35  
1.6 Purpose and rationale of the study ................................................................36  
2 STUDY OBJECTIVES  ...............................................................................................36  
2.1 Primary objective  ..........................................................................................36  
2.2 Secondary objectives ....................................................................................36  
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................37  
3.1 Study design .................................................................................................37  
3.2 Study design rationale ..................................................................................38  
3.3 Study Committees  .........................................................................................39  
4 SUBJECT POPULATION ..........................................................................................39  
4.1 Subject population description .....................................................................39  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 7/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
4.2 Rationale for the selection of the study population ......................................40  
4.3 Inclusion criteria  ...........................................................................................40  
4.4 Exclusion criteria  ..........................................................................................41  
4.5 Reliable contraception for women of chil dbearing potential  .......................43  
4.5.1  Definition of woman of childbearing potential .................................43  
4.5.2  Europe and Latin America ................................................................43  
4.5.3  North America  ..................................................................................44  
4.6 Medical history  .............................................................................................44  
5 TREATMENTS  ..........................................................................................................45  
5.1 Study treatment  .............................................................................................45  
5.1.1  Investigational treatment: description and rationale  .........................45  
5.1.2  Matching  placebo: description and rationale ....................................45  
5.1.3  Study treatment administration  .........................................................45  
5.1.4  Treatment assignment  .......................................................................45  
5.1.5  Blinding ............................................................................................46  
5.1.6  Unblinding ........................................................................................46  
5.1.6.1  Unblinding for final analyses ..................................................46  
5.1.6.2  Unblinding for SUSARs ..........................................................46  
5.1.6.3  Emergency procedure for unblinding ......................................47  
5.1.7  Study treatment supply .....................................................................47  
5.1.7.1  Study treatment packaging and labeling  .................................47  
5.1.7.2  Study treatment distribution and storage .................................48  
5.1.7.3  Study treatment dispensing .....................................................49  
5.1.7.4  Study treatment return and destruction ...................................49  
5.1.8  Compliance with study treatment  .....................................................49  
5.1.9  Study treatment dose adjustments and interruptions ........................50  
5.1.10  Premature discontinuation of study treatment  ..................................50  
5.1.11  Study- specific criteria for interruption / premature 
discontinuation of study treatment ....................................................51  
5.2 Previous and concomitan t therapy  ................................................................54  
5.2.1  Definitions  ........................................................................................54  
5.2.2  Reporting of previous/concomitant therapy in the CRF ...................54  
5.2.3  Allowed concomitant therapy ...........................................................54  
5.2.4  Forbidden concomitant therapy ........................................................55  
6 STUDY ENDPOINTS  ................................................................................................55  
6.1 Efficacy endpoints ........................................................................................55  
6.1.1  Double- blind treatment period  ..........................................................55  
6.1.1.1  Primar y efficacy endpoint  .......................................................55  
6.1.1.2  Secondary efficacy endpoints ..................................................56  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 8/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
6.1.1.3  Other efficacy endpoints .........................................................56  
6.1.2  Macitentan -treatment period  .............................................................56  
6.2 Safety endpoints  ...........................................................................................56  
6.2.1  Double- blind treatment period  ..........................................................56  
6.2.2  Macitentan -treatment period safety endpoints ..................................57  
6.3 Pharmacokinetic endpoints ...........................................................................57  
7 STUDY ASSESSMENTS  ...........................................................................................58  
7.1 Screening/baseline assessments  ....................................................................58  
7.2 Efficacy assessments  ....................................................................................59  
7.2.1  Hemodynamic measurements −  Right heart catheterization  ............59  
7.2.2  Hemodynamic measurements −  Hepatic vein catheterization  ..........60  
7.2.3  WHO functional class  .......................................................................60  
7.2.4  6-minute walk test .............................................................................61  
7.2.5  Borg d yspnea index ..........................................................................61  
7.2.6  Serum NT -proBNP  ...........................................................................61  
7.3 Safety assessments  ........................................................................................61  
7.3.1  Vital signs  .........................................................................................61  
7.3.2  Weight and height .............................................................................62  
7.3.3  Physical examination  ........................................................................62  
7.3.4  Child -Pugh classification and/or MELD Score assessment  .............62  
7.3.5  Laboratory assessments  ....................................................................62  
7.3.5.1  Type of laboratory ...................................................................62  
7.3.5.2  Laboratory tests  .......................................................................64  
8 SCHEDULE OF VISITS  ............................................................................................65  
8.1 Screening Period  ...........................................................................................65  
8.1.1  Screening (Visit 1)  ............................................................................65  
8.2 Double- blind treatment period  ......................................................................66  
8.2.1  Randomization (Visit 2)  ....................................................................66  
8.2.2  Week 4 (Visit 3) ................................................................................67  
8.2.3  Week 8 (Visit 4) ................................................................................67  
8.2.4  EOT -DB (sc heduled Visit 5) ............................................................68  
8.3 Open -label treatment period  .........................................................................68  
8.3.1  Week 16 (Visit 6) ..............................................................................68  
8.3.2  Week 20 (Visit 7) ..............................................................................69  
8.3.3  EOT -OL (scheduled Visit 8) .............................................................69  
8.4 EOS  ...............................................................................................................70  
9 STUDY COMPLETION AND POST -STUDY TREATMENT/MEDICAL 
CARE  ..........................................................................................................................70  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 9/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
9.1 Study completion  ..........................................................................................70  
9.2 Premature withdrawal from study ................................................................70  
9.3 Premature termination or suspension of the study ........................................71  
9.4 Medical care of subjects after study completion/ withdrawal from 
study ..............................................................................................................72  
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS  ...........................72  
10.1  Adverse events  ..............................................................................................72  
10.1.1  Definitions of adverse events ............................................................72  
10.1.2  Intensity of adverse events  ................................................................73  
10.1.3  Relationship to study treatment ........................................................73  
10.1.4  Adverse events associated to study design or protocol mandated procedures ........................................................................74
 
10.1.5  Reporting of adverse events ..............................................................74  
10.1.6  Follow-up of adverse events .............................................................74  
10.2  Serious adverse events  ..................................................................................74  
10.2.1  Definitions of serious adverse events ...............................................74  
10.2.1.1  Serious adverse events  .............................................................74  
10.2.1.2  Serious adverse events associated with the study design or protocol mandated procedures ............................................75
 
10.2.2  Reporting of serious adverse events .................................................75  
10.2.2.1  During screening period ..........................................................75  
10.2.2.2  During treatment period  ..........................................................75  
10.2.2.3  During 30-day follow-up period ..............................................75  
10.2.3  Follow-up of serious adverse events .................................................75  
10.2.4  After the 30 -day follow-up period ....................................................75  
10.2.5  Reporting procedures ........................................................................76  
10.3  Pregnancy  .....................................................................................................76  
10.3.1  Reporting of pregnancy ....................................................................76  
10.3.2  Follow-up of pregnancy ....................................................................76  
10.4  Study safety monitoring  ................................................................................77  
11 STATISTICAL METHODS  .......................................................................................77  
11.1  Analysis Sets  .................................................................................................77  
11.1.1  Screened Analysis Set  .......................................................................77  
11.1.2  Full Analysis Set ...............................................................................77  
11.1.3  Per-Protocol Set ................................................................................77  
11.1.4  Safety Set  ..........................................................................................77  
11.1.5  Other analysis sets  ............................................................................77  
11.1.6  Usage of the analysis sets  .................................................................78  
11.2  Variables  .......................................................................................................78  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 10/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
11.2.1  Primary efficacy variable  ..................................................................78  
11.2.2  Secondary efficacy variables  ............................................................78  
11.2.3  Other efficacy variables  ....................................................................79  
11.2.3.1  Double- blind treatment period  ................................................79  
11.2.3.2  Macitentan treatment period  ....................................................79  
11.2.4  Safety variables .................................................................................79  
11.2.4.1  Double-bl ind treatment period  ................................................79  
11.2.4.2  Macitentan treatment period  ....................................................80  
11.2.5  Other variables  ..................................................................................80  
11.3  Description of statistical analyses  .................................................................80  
11.3.1  Overall testing strategy  .....................................................................80  
11.3.2  Analysis of the primary efficacy variable(s)  .....................................80  
11.3.2.1  Hypotheses and statistical model ............................................80  
11.3.2.2  Handling of missing data  .........................................................80  
11.3.2.3  Main analysis  ...........................................................................81  
11.3.2.4  Supportive/sensitivity analyses ...............................................81  
11.3.2.5  Subgroup analyses ...................................................................82  
11.3.3  Analysis of the secondary  efficacy variable(s)  .................................82  
11.3.4  Analysis of the other efficacy variables  ............................................83  
11.3.5  Analysis of the safety variables  ........................................................83  
11.3.5.1  Adverse events  ........................................................................83  
11.3.5.2  Laboratory variables  ................................................................84  
11.3.5.3  Vital signs and body weight ....................................................84  
11.3.6  Analysis of other variables ...............................................................85  
11.4  Interim analyses  ............................................................................................85  
11.5  Sample size  ...................................................................................................85  
11.5.1  Sample size justification  ...................................................................85  
11.5.2  Sample size sensitivity  ......................................................................85  
12 DATA HANDLING  ....................................................................................................86  
12.1  Data collection  ..............................................................................................86  
12.2  Maintenance of data confidentiality  .............................................................87  
12.3  Database management and quality control  ...................................................87  
13 PROCEDURES AND GOOD CLINICAL PRACTICE  .............................................88  
13.1  Ethics and Good Clinical Practice  ................................................................88  
13.2  Independent Ethics Committee / Institutional Review Board  ......................88  
13.3  Informed consent ..........................................................................................88  
13.4  Compensation to subj ects and investigators  .................................................89  
13.5  Protocol adherence/compliance  ....................................................................89  
13.6  Protocol amendments ...................................................................................90  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 11/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
13.7  Essential documents and retention of documents .........................................90  
13.8  Monitoring ....................................................................................................91  
13.9  Investigator site file  ......................................................................................92  
13.10  Audit .............................................................................................................92  
13.11  Inspections ....................................................................................................92  
13.12  Reporting of study results and publication  ...................................................93  
14 REFERENCES  ............................................................................................................95  
15 APPENDICES  .............................................................................................................99  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 12/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
LIST OF TABLES 
Table 1  Visit and assessment schedule  ......................................................................27  
Table 2  Treatment effects (differences on log -scale as well as % reduction 
versus placebo), variability in integrated analysis of three studies 
(AC-052-366, AC-052-364 and AC-055-302) and associa ted sample 
size for 90% power in the PORTICO study. ................................................86  
  
LIST OF FIGURES 
Figure 1  Study design .................................................................................................38  
Figure 2 PK substudy design ....................................................................................100  
 
LIST OF APPENDICES 
Appendix 1  PORTICO PK substudy  ................................................................................99  
Appendix 2  Child -Pugh, MELD, and hepatic encephalopathy scales in 
classification of liver disease  ......................................................................105  
Appendix 3  Actelion guidelines for 6MWT  ...................................................................106  
Appendix 4  Borg dyspnea index ....................................................................................109  
Appendix 5  WHO functional classification of pulmonary hypertension .......................110  
Appendix 6  Laboratory abnormalities  ............................................................................111  
Appendix 7  Central la borator y alert flags ......................................................................113  
Appendix 8  List of protocol amendments ......................................................................114  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 13/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
LIST OF ABBREVIATIONS AND ACRONYMS 
6MWD  6-minute walk distance  
6MWT  6-minute walk tes t 
AE  Adverse event  
ALT   Alanine aminotransferase  
ANCOVA   Analysis of Covariance  
AST   Aspartate aminotransferase 
ATS   American Thoracic Society  
AUC   Area under plasma concentration -time curves  
AUC 0-∞  Area under the plasma concentration -time curve from zero to 
infinity  
AUC 0-t  Area under the plasma concentration -time curve from time zero to 
time t 
AUC τ  Area under the plasma concentration -time curve during one dosing 
interval  
BDI  Borg Dyspnea i ndex 
BLQ   Below limit of qualification  
BP  Blood pressure 
BSA   Body surface area  
BUN   Blood urea nitrogen 
CI  Cardiac index  
Cmax  Maximum plasma concentration  
CO  Cardiac output 
CRA   Clinical Research Associate  
eCRF   electronic Case Report Form  
CRO  Contract Research Organization  
CV  Coefficient of Variation  
CYP   Cytochrome P450 
DBP  Diastolic blood pres sure 
DoA   Delegation of Authority  
ECG   Electrocardiogram  
EDTA   Ethylenediaminetetraacetic acid  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 14/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
EMA   European Medicines Agency 
EOMT   End of macitentan treatment  
EOS   End of Study 
EOT -DB  End of Treatment  (double -blind)  
EOT -OL  End of Treatment (open- label)  
ERA   Endothelin receptor antag onist 
ERS  European Respiratory Society 
ET-1  Endothelin-1 
ETA  Endothelin receptor A  
ETB  Endotheli n receptor B  
FAS  Full Analysis Set 
FDA   Food and Drug Administration 
GCP   Good Clinical Practice  
GGT   Gamma -glutamyl transferase  
GMP   Good Manufacturing Practice  
GMR   Geometric Mean Ratio  
HIV  Human immunodeficiency virus 
HR  Heart rate 
HVC   Hepa tic vein cat heterization  
HVPG  Hepatic venous pressure gradient 
IB  Investigator’ s Brochure  
ICF  Informed Consent Form 
ICH  International Conference on Harmonisation 
IEC  Independent Ethics Committee  
ILSDRB   Independent Liver Safety Data Review Board  
INR  International Normalized Ratio  
IRB  Institutional Review Board  
ISF  Investigator Site File 
IUD  Intrauterine device  
i.v.  Intravenous 
IxRS   Interactive Voice/Web Response System  
LDH   Lactate dehydrogenase  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 15/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
LFT   Liver function test 
LOQ   Limit of quant ification  
LVEDP   Left ventricular end diastolic pressure 
MedDRA   Medical Dictionary for Regulatory Activities  
MELD   Model for End- stage Liver Disease  
mPAP   Mean pulmonary arterial pr essure  
mRAP   Mean right atrial pre ssure  
MTS   Macitentan Treatment Set 
NT-proBNP   N-terminal pro -hormone brain natriuretic peptide  
OLT   Orthotopic liver transplantation  
PAH  Pulmonary arterial hyp ertension 
PAWP   Pulmonary artery wedge press ure 
PDE5i   Phosphodiesterase type 5 inhibitor  
PH  Pulmonary hypertensi on 
PK  Pharmacokinetic  
PoPH   Portopulmonary hypertension 
PPS  Per-protocol Set 
PT-INR  Prothrombin time and  International Normalized Ratio  
PVR   Pulmonary vascular r esistance  
RHC   Right heart catheterization  
SAE   Serious adverse event  
SAP  Statistic al Analysis Plan  
SBP  Systolic blood pre ssure  
s.c.  Subcuta neous 
SD  Standard deviation  
sGC  Soluble guanylate cyclase (stimulator, riociguat)  
SIV  Site initiation visit  
SOC   System organ class  
SOP  Standard O perating Procedure  
SUSAR   Suspected une xpected serious adverse reaction  
SVO 2  Venous oxygen saturation 
TIPS   Transjugular intrahepatic portosystemic shunt 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 16/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
tmax  Time to reach maximum plasma concentration  
TPR  Total pulmonary resistance  
ULN   Upper limit of the normal range 
WHO   World Healt h Organization  
WU  Wood Units 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 17/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
PROTOCOL SYNOPSIS AC-055-404 
TITLE  A randomized, double -blind, placebo -controlled, prospective, 
multicenter, parallel group  study to assess the safety and 
efficacy of macitentan in patients with portopulmonary 
hypertension 
ACRONYM  PORTICO  
POR topulmonary hypertension T reatment w Ith ma Citentan  
─ a randO mized clinical trial 
OBJECTIVES  Primary objective  
• To evaluate the effect of macitentan on pulmonary vascular 
resistance (PVR) as compared to placebo in patients with portopulmonary hypertension (PoPH). 
Secondary objectives  
• To evaluate the effect of macitentan as compared to placebo on cardio-
pulmonary hemodynamics, hepatic portal vein 
pressure, disease severity, and exercise capacity in patients 
with PoPH.  
• To evaluate the saf ety and tolerability of macitentan as 
compared to placebo in patients with PoPH. 
• To evaluate the pharmacokinetics (PK) of macitentan and its active metabolite ACT -132577 in patients  with PoPH  (PK 
substudy). 
DESIGN  Randomized, double -blind, placebo -control led, prospective, 
multicenter, parallel group study . 
PERIODS  The study comprises a 28 -day Screening period, followed by a 
12-week double -blind treatment period. All subjects completing 
the double -blind treatment period as scheduled will have the 
opportuni ty to enter a 12- week open -label treatment period with 
macitentan. A 30 -day Safety follow up period follows 
discontinuation of study treatment (double- blind or open- label) 
before the End of Study (EOS) for a subject can occur.  
PLANNED DURATION  Approximate ly 18 months from first subject , first visit to last 
subject , last visit.  
SITE(S)  
/ COUNTRY(IES)  45 sites in 7 countries (planned):  
BRA, CZE, DEU, ESP, FRA, GBR, USA. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 18/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
SUBJECTS / GROUPS  84 subjects in 2 groups; 42 subjects per group (randomized 1:1).  
Randomization will be stratified by region (Europe/North 
America/Latin America)  and by use of background pulmonary 
arterial  hypertension ( PAH )-specific therapy  (yes/no). 
INCLUSION CRITERIA  1) Signed informed consent prior to any study -mandated 
procedure  
2) Male or female ≥  18 years of age with symptomatic PoPH: 
• Documented diagnosis of portal hypertension 
• PAH by right heart catheterization at screening:  
− Mean pulmonary arterial pressure (mPAP)  
≥ 25 mmHg 
− Pulmonary artery wedge pressure (PAWP) or left 
ventricular end  diastolic pressure (LVEDP)  
≤ 15 mmHg 
3) PVR ≥ 4 Wood Units (WU) or ≥ 320 dyn.s.cm-5 at 
screening1 
4) 6-minute walk distance  (6MWD) ≥ 50 m at screening 
5) Women of childbearing potential must:  
a) Have a negative serum pregnancy test during screening 
and a negative urine pregnancy test on Day 1, and  
b) Agree to use reliable methods of contraception from 
screening up to 30 days after study treatment 
discontinuation, and 
c) Agree to perform monthly pregnancy tests up to 30 days after study treatment discontinuation . 
EXCLUSION CRITERIA  1. PAH due to any other condition than portal hypertension  
2. Severe hepatic impairment, as defined by Child -Pugh Class 
C liver disease or Model for End- stage Liver Disease  
(MELD ) score ≥ 19  
3. Unstable liver disease (in the opinion of the investigator) 
4. History of t ransjugular intrahepatic portosystemic shunt 
(TIPS)  within 6 months prior to randomization 
5. Documented severe obstructive or restrictive lung disease (in the opinion of the investigator)  
                                                 
  
1 Cardiac output measured by thermodilution technique only. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 19/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
6. Documented pulmonary veno -occlusive disease  
7. Systolic blood pressure (SBP) < 90 mmHg at Screening 
8. Body weight < 40 kg at Screening  
9. Patients undergoing dialysis 
10. Initiation of diuretics or beta blockers within 1 week prior to 
baseline right hear t catheterization (RHC) or  patients on 
oral diuretics  or beta blockers  in whom the dose has not 
been stable for at least 1  week prior to baseline RHC  
11. Hemoglobin < 100 g/L at Screening 
12. Serum aspartate aminotransferase (AST) and/or alanine 
aminotransferase ( ALT) ≥ 3 × the upper limit of the normal 
range (ULN) at Screening  
13. Bilirubin ≥  3 mg/dL at Screening  
14. Grades 2, 3, or 4 hepatic encephalopathy  
15. History of liver transplantation  
16. Documented  hepatocellular carcinoma  
17. Documented  schistosomiasis infection  
18. Gastroin testinal bleeding or esophageal variceal  bleeding   
< 3 months prior to randomization 
19. Recently started  (< 3 months prior to randomization) or 
planned cardio- pulmonary rehabilitation program based on 
exercise  
20. Treatment with  calcium channel blockers,  endothelin 
receptor antagonists (ERA), intravenous/subcut aneous 
(i.v./s.c.) or oral prostanoids  within 3 months prior to 
randomization 
21. Initiation, change in dose or discontinu ation of 
phosphodiesterase type 5 inhibitors (PDE5i), or soluble 
guanylate cyclase stimul ator within 3 months prior to 
randomization 
22. Treatment with interferon within  3 months prior to 
randomization 
23. Treatment with any investigational drug within 3 months 
prior to randomization 
24. Treatment with strong cytochrome P450 (CYP) 3A4 
inducers (e.g., carbamazepine, rifampin, rifampicin, 
rifabutin, rifapentin, phenobarbital, phenytoin, and 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 20/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
St. John ’s wort) within 4 weeks prior to randomization  
25. Treatment with strong CYP3A4 inhibitors 
(e.g., ketoconazole, itraconazole, voriconazole, 
clarithromycin, telithromy cin, nefazodone, ritonavir, 
boceprevir, telaprevir, saquinavir, lopinavir , fosamprenavir, 
darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, 
indinavir , and paritaprevir ) within 4 weeks prior to 
randomization 
26. Known hypersensitivity to macitentan  or its excipients or 
drugs of the same class  
27. Pregnancy , breastfeeding , or intention to become pregnant 
during the study 
28. Known concomitant life -threatening disease with a life 
expectancy of < 6 months 
29. Any known factor or disease that might interfere with 
treatment compliance, study conduct, or interpretation of 
results  
30. Suspected or known current drug or alcohol abuse. 
STUDY TREATMENTS Investigational treatment  
Macitentan film- coated tablet 10 mg once daily .  
Comparator and/or placebo 
During the double -blind tr eatment period: Matching placebo 
tablet once daily . 
CONCOMITANT 
THERAPY  Allowed concomitant  therapy  
Oral PDE5i, inhaled prostacyclin analogues, soluble guanylate 
cyclase (sGC) stimulator  are allowed if present for at least 
3 months prior to randomization at a stable dose ( which must 
remain unchanged during the double-blind treatment period 
unless the patient experiences worsening of PAH).  
Treatment with oral diuretics is allowed if ongoing at a stable 
dose for at least  1 week prior to baseline right heart  
catheterization; the dose may be optimized during the treatment 
period. 
Beta blockers are allowed if present for at least 1 week prior to 
baseline right heart catheterization  at a stable dose (which 
should remain unchanged during the study). If discontinuation 
of beta blockers occurs during the study the patient should 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 21/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
complete the study as scheduled.  
During the open- label period, i.v. and s.c. prostanoid therapy 
(e.g., epoprostenol, treprostinil) is permitted at any time.  
The following antiviral hepatiti s C medications are permitted: 
simeprevir, sofosbuvir, daclatasvir, ombitasvir, dasabuvir, 
ledipasvir, etravirine, raltegravir, maraviroc, and ribavirin. 
Forbidden concomitant medication 
• ERAs (e.g., bosentan, ambrisentan) 
• During the double -blind period, i.v./s.c. and oral prostanoid 
therapy  (e.g., epoprostenol, treprostinil) is forbidden  
• Calcium channel blockers 
• Strong CYP3A4 inducers (e.g., carbamazepine, rifampin, 
rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, 
and St. John’ s wort) 
• Strong CYP3A4 inhibitors ( e.g., ketoconazole, itraconazole, 
voriconazole, clarithromycin, telithromycin, nefazodone, 
ritonavir, lopinavir , fosamprenavir, darunavir, tipranavir, 
atazanavir, nelfinavir, amprenavir, i ndinavir, boceprevir, 
telaprevir, paritaprevir and saquinavir)  
• Treatment with interferon  
• Any other investigational drug. 
ENDPOINTS  Double -blind treatment period  
(Baseline is the last assessment prior to initiation of 
double-blind treatment).  
Primary efficacy endpoint  
Relative change from Baseline to Week 12 in PVR.  
Secondary efficacy endpoints  
• Change from Baseline to Week 12 in mean right atrial 
pressure (mRAP), mPAP, cardiac index (CI), total 
pulmonary resistance (TPR), and mixed venous oxygen 
saturation (SVO 2), all measured at rest  
• Change from Baseline to Week 12 in 6MWD 
• Change from Baseline to Week 12 in WHO functional class  
• Change from Baseline to Week 12 in NT- proBNP . 
Other efficacy endpoints  
• Change from Baseline to Week 12 in hepatic venous 
pressure gradient (HVPG)  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 22/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• Change from Baseline to Week 12 in Borg dyspnea index . 
Macitentan treatment period (all patients receiving macitentan 
in either double -blind or open- label treatment periods). 
(Macitentan Baseline is the last assessment prior to initiation of 
macitentan treatment). 
• Change from macitentan Baseline to each time point in  
WHO functional class  
• Change from macitentan Baseline to each time point in 
NT-proBNP  
• Change from  macitentan  Baseline to each time point in 
6MWD  
• Change from macitentan Baseline to each time point in 
Borg dyspnea index . 
Safety  endpoints  
Double- blind treatment period 
(Treatment -emergent is defined as from first intake of study 
treatment  until to end of double -blind treatment + 30 days or 
start of open- label treatment, whichever occurs first) . 
• Treatment -emergent deaths  
• Treatment -emergent adverse events (AEs)  
• Treatment -emergent AEs leading to premature 
discontinuation of double- blind study treatment  
• Treatment -emergent serious adverse events (SAEs)  
• Proportion of patients with treatment -emergent ALT and/or 
AST abnormality ( ≥ 3, ≥ 5, and ≥  8 × ULN)  
• Proportion of patients with treatment -emergent ALT and/or 
AST abnormality ( ≥ 3 × ULN) associated with  total 
bilirubin ≥ 2 ×  ULN  (and increased as compared to 
baseline)  
• Proportion of patients with treatment -emergent hemoglobin 
abnormality (< 1 00 g/L, and < 80 g /L) 
• Treatment -emergent marked lab abnormalities  
• Change from Baseline to End of Treatment (double -blind) 
(EOT -DB) in vital signs  
• Change from Baseline to EOT -DB in laboratory variables  
• Change from Baseline to EOT -DB in Child -Pugh 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 23/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
classific ation  
• Change from Baseline to EOT -DB in MELD Score. 
Macitentan treatment period (all patients receiving macitentan 
in either double -blind or open -label treatment periods)  
Macitentan treatment -emergent is defined as from first intake of 
macitentan up to EOS (i.e., 30 days after discontinuation of 
macitentan treatment). End of macitentan treatment (EOMT) is 
defined as EOT -DB or End of Treatment (open -label) 
(EOT -OL), whichever comes last. Macitentan Baseline is 
defined as last assessment prior to first intake of macitentan. 
• Macitentan treatment -emergent  deaths 
• Macitentan treatment -emergent  AEs  
• Macitentan treatment -emergent  AEs leading to premature 
discontinuation of macitentan treatment  
• Macitentan treatment -emergent  SAEs  
• Proportion of patients with macitentan treatment -emergent 
ALT and/or AST abnormality ( ≥ 3, ≥ 5, and ≥  8 × ULN) up 
to EOMT  
• Proportion of patients with macitentan treatment -emergent 
ALT and/or AST abnormality ( ≥ 3 ULN) associated with  
total bilirubin ≥  2 × ULN  (and increased as compared to 
baseline)  up to EOMT  
• Proportion of patients with macitentan treatment -emergent 
hemoglobin abnormality (< 100 g/L, and < 80 g/L) up to 
EOMT  
• Macitentan t reatment -emergent marked lab abnormalities up 
to EOMT  
• Change from macitentan Baseline to EOMT  in vital signs  
• Change from macitentan Baseline to EOMT  in laboratory 
variables  
• Change from macitentan Baseline to EOMT  in Child -Pugh 
classification  
• Change from macitentan Baseline to EOMT  in MELD 
Score. 
ASSESSMENTS  Refer to the schedule of assessments in  Table 1. 
STATISTICAL 
METHODOLOGY  Double -blind treatment period  
• Analysis sets 
The Full Analysis Set (FAS) includes all randomized  patients 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 24/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
who received at least one dose of study treatment  and who have  
a baseline value for the primary endpoint (PV R).  
The Per -Protocol Set (PPS) comprises all patients included in 
the FAS without major protocol deviations that affect the main 
analysis of the primary efficacy variable.  
The Safety Set includes all patients who received at least one 
dose of study treatment . 
The PK set comprises all patients from the FAS who did not 
deviate from the protocol in a way that might affect the 
evaluation of the PK  endpoints. 
• Primary endpoint  
The primary endpoint is the r elative change from baseline to 
Week 12 in PVR. 
• Statistic al hypotheses 
The null hypothesis is that the treatment difference (macitentan 
minus placebo) in mean relative change from baseline to 
Week  12 in PVR is greater than or equal to zero. 
The alternative hypothesis is that the treatment difference in 
mean relative change from baseline in PVR is less than zero.  
• Type- I and - II errors and power 
The type I error (α) is set to 0.025 (one -sided), the type II error 
is set to 0.10 and the power to 90%. • Sample size calculation  
An integrated analysis of two bosentan stud ies, BENEFIT 
(AC-052- 366) and EARLY (AC -052- 364), and the 
hemodynamic substudy of SERAPHIN (AC -055-302) 
suggested that the treatment group difference is expected to be 
around −0.31 on log scale (95% confidence interval : −0.38, 
−0.23) and that the within group standard deviation is around 
0.41 on log scale. Under these assumptions, 76 evaluable 
patients will be needed for 90% power (38 patients per group). Accounting for 10% non-
evaluable patients, approximately 
84 patients will need to be randomized. 
• Primar y analysis 
The primary analysis will be performed on the FAS. 
The Week 12 versus baseline ratio in PVR will be 
log transformed (base e) and analyzed using an Analysis of 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 25/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Covariance (ANCOVA) with factors for treatment group, 
region and background PAH -specif ic therapy and a covariate 
for baseline log PVR. The treatment group difference in mean 
change from baseline (on log scale) and its 95% confidence 
interval  will be estimated based on the model. The Geometric 
Mean Ratio (GMR, macitentan versus placebo) and its 95% 
confidence interval  will be obtained by exponentiation. The null 
hypothesis will be rejected if the entire 95% confidence interval  
is below one. 
The treatment effect will be expressed as (GMR -1) × 100%, 
where a negative value indicates a reduction of PVR in the 
macitentan group as compared to the placebo group.  
If PVR cannot be calculated due to missing PAWP but mPAP and cardiac output ( CO) are available for the same visit, PAWP 
will be imputed. Post- baseline PVR values obtained earlier than 
Week 1 2 will be carried forward . 
For patients where no 
post- baseline PVR measurement is available, data will be 
imputed. 
Secondary analyses 
Secondary efficacy variables will be analyzed for the FAS at α=0.025 (one -sided) using 95% confidence i ntervals
. No 
correction for multiple testing will be applied for these analyses.  
• Safety endpoints  
Safety data will be summarized using descriptive statis tics. 
Safety analyses will be performed on the Safety Set.  
• Interim analysis 
No interim analysis is planned . 
Macitentan treatment period  
• Analysis sets 
The Macitentan Treated Set (MTS) consists of all patients who  
received at least one dose of macitentan in the double -blind 
period or open- label period. 
• Statistical hypotheses  
No formal hypothesis testing will be performed. Efficacy and 
safety data will be summarized using descriptive statistics.  
STUDY COMMITTEES  A Steering Committee will help design the study , provide 
guidance on the study conduct  evaluation  of the results, and 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 26/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
support study publications.  
An Independent Liver Safety Data Review Board (ILSDRB, an 
external expert committee of hepatologists) will provide 
ongoing assessment and advice regarding se rious hepatic 
adverse events of special interest that require further evaluation during the study as per ILSDRB charter.  
SUB-STUDIES  PK substudy  
This substudy is planned during the open -label  treatment period 
and described under the same protocol. It will  be conducted in 
participating  centers. In these centers, all patients continuing in  
the open- label treatment period will be offered to participate in 
the substudy. 
At least 20 patients eligible for the open -label treatment period  
will be enrolled . The pla sma PK variables  will be derived by 
non-compartmental analysis of the plasma concentration -time 
profiles. Peak maximum plasma concentration (C max) and area 
under the plasma concentration- time curve during one dosing 
interval (AUC t) values are assumed to be  log- normally 
distributed. 
PK endpoints are for both macitentan and ACT-132577: 
• The area under the plasma concentration -time curve during 
one dosing interval (AUC t).  
• Maximum plasma concentration (C max) during a dosing 
interval.  
• The time to reach maximum plasma concentration (t max) 
during a dosing interval. 
 
Macit entan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 27/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 Table 1 Visit and assessment schedule  
PERIODS  Name  SCREENING  DOUBLE -BLIND TREATMENT  OPEN -LABEL TREATMENT   FOLLOW -UP 
 Duration  28 days  12 weeks  12 weeks   30 days  
VISITS  Numb er 1 2 3/4 5 6/7 8 U1, U2…   
 Name  Screening  Random -
ization  Visits 3/4  EOT -DB1 Visits 6/7  EOT -OL1 Unscheduled visit 2 EOS3 
 Time  Day −28 Day 1  Weeks 4/8  
(± 4 days)  Week 12  
(± 4 days)  Weeks 16/20  
(± 4 days)  Week 24  
(± 4 days)  Any day between Day 
1 and We ek 24  EOT -DB/OL   
+ 30–33 days  
Informed consent  X        
Medical history  X        
Demographics  X        
Concomitant therapy  X X X X X X X  
Physical examination4 X X X X X X X  
Vital signs  X   X  X X  
Height5 and weight  X   X  X   
Laboratory tests6 X7 X X X X X X  
Serum p regnancy test X X8 X X X X X X15 
Child -Pugh assessment  and/ or 
MELD Score  X   X  X   
Right heart catheterization9 X   X     
Hepatic vein catheterization10 X   X11     
6MWT & BDI  X X X X X X X  
WHO  functional class  X X X X X X X  
NT-proBNP   X  X  X X  
PK substudy      X12    
Study drug dispensing/  return13  X X X X X   
Adverse Events14 X X X X X X X X 
Serious Adverse Events14 X X X X X X X X 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 28/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
6MWT = 6 -minute walk test; AE = adverse event; BDI = borg dyspnea i ndex; CRF = case report form; EOT -DB = end of tre atment  (double -
blind); EOT -OL = end of treatment  (open -label); EOS = end of stu dy; HVC = hepatic vein catheterization;  MELD = Model for End-stage Liver 
disease ; PK = pharmacokinetics;  PT-INR =  prothrombin time and internationa l normalized ratio ; RHC = right heart catheterization ; SAE = 
serious adverse event; WHO = World Health Organization.  
 
1 If subject does not reach Week 12 (Visit 5) or does not enter into open- label phase, EOT -DB visit must be performed including RHC, follo wed 
by EOS after 30 days. If a subject enters open -label  phase, but does not reach Week 24 (Visit 8 ), EOT -OL visit must be performed but without 
RHC, followed by EOS after 30 days.  
2 Unscheduled visits may be performed at any time during the study and may include all or some of the indicated assessments, based on the 
judgment of the investigator.  
3 Visit may be performed by phone.  
4 Data not collected in the CRF; abnormal findings to be recorded as Adverse Events . 
5 Height recorded at Screening only . 
6 Includes hematology, general blood chemistry, liver functions tests, serum bile acids, PT -INR. To be performed monthly during study conduct . 
7 Eligibility to be assesse d using Screening lab oratory data  only 
8 Urine dipstick pregnancy test to be performed in addition to serum .  
9 Cardiac output to be measured using thermodilution technique only . 
10 HVC is not required at sites that do not perform the procedure routinely.  
11 To be performed on or within 7 days prior  to EOT -DB (if previously performed at Baseline) . 
12 Separate PK substudy Informed Consent F orm to be completed prior to any substudy procedure. Can be performed at any time point  on or  
between Visits 6 and 7.  
13 Scheduled study treatment  dispensing/return procedures may be adapted according to the site practice. 
14 All AEs and SAEs that occur after signing the Informed Consent Form and up to 30 days after study treatment discontinuation must be 
reported . 
15 Urine dipstick test. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 29/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
PROTOCOL 
1 BACKGROUND 
1.1 Indication 
Portopulmonary hypertension (PoPH) is defined as pulmonary arterial hypertension 
(PAH) associated with portal hypertension with or without underlying hepatic disease. PoPH belongs to Group I (PAH) of the WHO classification of pulmonary hypertension (PH) [Simmoneau 2013]. Diagnosis of PoPH is based on pulmonary hemodynamic 
criteria for PAH obtained via right heart catheterization  (RHC) , including  mean 
pulmonary arterial pressure (mPAP) ≥  25 mmHg at rest, mean pulmonary artery wedge 
pressure (PA WP) ≤  15 mmHg, within the context of portal hypertension: portal vein 
pressure > 10 mmHg or hepatic venous pressure gradient (HVPG) > 5 mmHg. 
The pathogenesis of PoPH is not fully understood. The development of PoPH appears to 
be independent of the cause and severity of portal hypertension, but rather as a consequence of the portal hypertension itself in genetically predisposed patients  
[Cartin -Ceba 2014]. Although the pulmonary vascular changes in PoPH are 
indistinguishable from those of other forms of PAH , the pathological processes that lead 
to such changes are not completely understood. It is likely that a combination of aberrant vasoactive and angiogenic signaling due to portal hypertension coupled with a hyperdynamic circulatory state resulting in disruption of the normal hepatopulmonary 
circulation, increased vascular shear/mechanical stress in the lung vasculature, and thus the pathogenic changes observed in PoPH [ Al-Naamani 2013].  
On average, PAH is diagnosed 4 to 7 years after the diagnosis of portal hypertension [Halank 2006]. The most common presenting symptom of PoPH is dyspnea on exertion. 
Other nonspecific symptoms include syncope, chest  pain, fatigue, light -headedness, 
orthopnea, and edema. However, patients often present no specific symptoms indicative of PAH, and PoPH is most commonly diagnosed during evaluation for liver 
transplantation. 
1.2 Epidemiology and natural history 
Although PoPH is an uncommon complication of portal hypertension, it accounts for a sizeable percentage of patients with PAH. Recent registries estimate the prevalence of PoPH to be approximately 5–10% of all PAH  patients [ Humbert 2006, Krowka 2012]. 
Similarly , the prevalence of PoPH is described to be 5 –8.5% amongst all portal 
hypertension patients undergoing evaluation for liver transplantation in the three largest registries reported to date [ Ramsay 1997, Colle 2003, Krowka 2006]. The mean age at 
presentation of PoPH is during the fifth decade of life  (49 ± 13 years). No differ ences in 
prevalence between men and woman are observed [ Golbin 2007 ]. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 30/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
The prognosis for patients with PoPH is poor. Historically, 5- year survival outcome was 
less than 10% [ Roba lino 1991] but in the modern era with PAH -specific pharmacological 
intervention available, survival outcomes had improved in the US to 40% at 5 years but 
still with a 4 -fold risk of death versus idiopathic PAH [ Benza 2 010]. In France, survival 
outcomes at 5 years were reported to be comparable to that of i diopathic PAH at 68%  
[Le Pavec 2008 ]. Causes of death reflect the existence of two serious illnesses: advanced 
liver disease and PAH  with right heart failure  [Safdar 2012].  
1.3 Current management  
The European Respiratory Society (ERS) Task Force on Pulmonary -Hepatic Vascular 
Disorders [ Rodriguez- Roisin 2004] outlines PoPH treatment options as including: 
intravenous (i.v.) prostacyclin (epoprostenol), prostacyclin analogs (inhaled iloprost), and 
endothelin receptor antagonists ( [ERA]s bosentan). In the intervening time, clinical 
experience with othe r newly approved PAH medications, including the phosphodiesterase 
type 5 inhibitor (PDE5i) sildenafil [ Reichenberger 2006, Gough 2009, Hemnes 2009,  
Hollatz 2012], inhaled and i .v. treprostinil (prostacyclin analog) [ Reichenberger 2006, 
Hollatz 2012, Sakai 2009], and the ERA ambrisentan [ Cartin -Ceba 2011, Halank 2011, 
Condliffe 2014], ha s been reported suggesting beneficial effects of vasodilator therapy in 
PoPH . This clinical experience is  limited mainly to single -center, open -label studies.  
As a whole, clinical experience with ERAs has been favorable in terms of efficacy and safety, as reported in the l iterature. Studies with bosentan both as a monotherapy  
[Hoeper 2005, Hoeper 2007] and in combination with sildenafil [ Savale 2013] reporte d 
improvements in hemodynamic and exercise capacity. As with clinical studies of bosentan in PAH, treatment was discontinued in a proportion of patients after transient elevation in liver transaminases was detected. In constrast, in the three studies repor ted to 
date on ambrisentan use in PoPH, no drug -related liver safety events were reported. No 
randomized clinical trial has been undertaken specifically in PoPH, leaving a paucity of data to demonstrate efficacy or safety of any PAH medication in PoPH. The PATENT -1 
study of riociguat in PAH (a soluble guanylate cyclase [ sGC] stimulator) showed 
improvement in the primary endpoint of change in 6- minute walk test ( 6MWT) ; however, 
no data on the subgroup of 13 PoPH patients were reported [ Ghofrani 2013 ].   
Orthotopic liver transplantation (OLT) is indicated in advanced liver disease, including portal hypertension, but is contra -indicated in patients who are compromised in terms of 
their cardiopulmonary hemodynamics, including PoPH. The ERS Task Force [Rodriguez- Roisin 2004] provides an algorithm for PoPH indicating patients with mild 
(mPAP <  35mmHg) disease as eligible for OLT; patients with moderate (mPAP  
≥ 35–45 mmHg) disease  should receive pulmonary vasodilator therapy prior to OLT to 
try to stabilize cardiopulmonary hemodynamics (i.e., lower both mPAP and pulmonary vascular resistance [PVR ]); and for patients with severe (mPAP > 45 mmHg)  disease, 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 31/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
OLT is contraindicated but chronic vasodilator therapy to manage PAH should be 
considered.  
1.4 Endothelin-1 and pulmonary hypertension  
Endothelin- 1 (ET -1), a 21 amino acid peptide, is one of the most potent vasoconstrictors 
and mitogens for smooth muscle  cells, and contributes to increased vascular tone and 
proliferation in pulmonary vasculopathy [ Galiè 2004 ].  
There are 2 distinct receptors for ET -1: endothelin receptor A (ET A) and endothelin 
receptor B (ET B). The 2 receptors have unique binding locations and affinities for the 
endothelin peptide [ Benigni 1995, Massaki 1998 ]. The ET A receptors are expressed on 
pulmonary vascular smooth muscle cells, whereas ET B receptors are present both on 
pulmonary vascular cells and on smooth muscle cells.  
When activated, the ET A receptors located in pulmonary vascular smooth muscle cells 
mediate a potent vasoconstrictive response, and ET B receptors on endothelia l cells 
mediate vasodilatation via increased production of nitric oxide and prostacyclin  
[Hirata 1993, de Nucci 1988]. ET- 1 is also known to be a potent mitogen, with the ability 
to induce cell proliferation in vascular smooth muscle cells. It has been shown that both 
the ETA and ET B receptors mediate the mitogenic action of ET -1 [Clarke 1989,  
Chua 1992, Davie 2002, Sugawara 1996].  
Laboratory and clinical investigations have clearly shown that ET -1 is overexpressed in 
several forms of pulmonary vascular disease. ET -1 is likely a major player in the 
vasodilator and vasoconstrictor imbalance, as well as in the abnormal pulmonary vascular remodeling present in the development and progression of PH o f various etiologies 
[Stewart 1991, Giaid 1993].  
1.5 Macitentan 
Macitentan 10 mg (Opsumit®) is approved in the US, Europe, Australia, Canada, Israel, 
Mexico, and Switzerland for the treatment of PAH. 
1.5.1 Nonclinical results  
Macitentan is an orally active, non -peptide, potent dual ET A and ET B. Macitentan shows 
dose- dependent efficacy in nonclinic al models of hypertension and PH, and is 
approximately 10 times more potent than bosentan (Tracleer®). In nonclinical safety 
studies, no effects on normal physiological  functions or electrocardiogram variables, 
including cardiac repolarization, were observed – with the exception of a decrease in 
arterial blood pressure (BP) observed in a cardiovascular study in dogs. Macitentan has 
no genotoxic potential. In the pivotal 26- week and 39- week toxicity studies, the 
exposures in animals found at the no-observed- adverse -effect levels were above the 
anticipated clinical exposures and provided a margin of safety for studies in humans. A 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 32/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
study conducted in hairless rats showed tha t macitentan is not phototoxic in vivo . 
Macitentan does not bind relevantly to melanin. Reproductive toxicity studies showed 
that macitentan is teratogenic without affecting male or female fertility. Teratogenicity is considered to be an ERA class effect.  
More detailed information on macitentan can be found in the Investigator’ s Brochure  (IB) 
[Macitentan IB ]. 
1.5.2 Clinical information  
1.5.2.1 Phase 1 studies 
During the Phase 1 program, more than 200 healthy subjects and about 30 patie nts (with 
renal and hepatic impairment) were treated with macitentan. Macitentan was well tolerated in all studies.  The most  frequently reported adverse event ( AE) was headache. 
No clear dose relationship could be discerned for any AE. Eight cases of asymptomatic increases in aminotransferases were observed in the Phase 1 program ( 6 received 
macitentan, 2 received placebo). Of these increases, 3 (all 3 subjects  received macitentan) 
were > 3  × the upper limit of the normal range (ULN), and none exceeded 4 ×  ULN. All 
cases resolved within 14 days of observation. 
The potential for a mutual drug- drug interaction between macitentan and sildenafil was  
studied in a randomized, crossover study. The pharmacokinetic ( PK) profile of 
macitentan and its metabolite ACT -132577 (the only pharmacologically active metabolite 
circulating in plasma) was not affected by sildenafil treatment. In addition, although 
treatment with macitentan resulted in increased maximum plasma concentration  (C
max) 
and area under the plasma concentr ation -time curve during one dosing interval  (AUC τ) 
values, the PK profile of N -desmethyl sildenafil was not affected. No dose adjustment of 
either compound is required when given concomitantly.    Concomitant treatment with cyclosporine was well tolerated,  and did not have any 
clinically relevant effect on the exposure to macitentan or its metabolites ACT -132577 
and ACT-373898 at steady- state.  
Minor differences in the PK parameters of macitentan and ACT -132577 were noted 
between healthy subjects and those with severe renal impairment. However, marked 
differences in the PK parameters of the pharmacologically inactive metabolite, ACT -373898, were noted between healthy subjects and those with severe renal 
impairment. The safety profile of macitentan was simila r in healthy subjects and those 
with severe renal impairment.  
More detailed information on macitentan can be found in the I B [Macitentan IB ]. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 33/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
1.5.2.1.1 Hepatic impairment 
The effects of mild, moderate or severe hepatic impairment due to liver cirrhosis on the 
PK of a single oral dose of 10 mg macitentan  were studied in a dedicated Phase 1 study . 
No correlation between the severity of hepatic impairment and the mean plasma 
concentrations of macitentan, ACT -132577, and ACT -373898 were apparent. Minor 
differences between PK parameters of macitentan, ACT -132577, and ACT -373898 were 
observed between healthy subjects and subjects with mild, moderate, and severe liver impairment. These differences were not considered to be clinically relev ant, therefore no 
dose adjustments are required. There was no correlation between laboratory components of Child- Pugh score and area under the plasma concentration -time curve from zero to 
infinity (AUC
0-∞), area under the plasma concentration -time curve from time zero to time 
t (AUC 0-t), C max, and t ½. No relevant differences in macitentan and ACT -132577 protein 
binding were observed between subjects with mild, moderate, or severe hepatic impairment and healthy subjects. A reduction in the extent of plasma protein binding of the inactive minor metabolite, ACT -373898, was observed, and the extent of the decrease 
correlated with the severity of hepatic impairment. This is not expected to be clinically relevant and is not expected to influence clinical outcome.  
Only one subject with hepatic impairment experienced elevations in liver function tests (LFTs) that were considered by the investigator as clinically significant. The inc reases in 
alanine aminotransferase [ALT], aspartate aminotransferase [AST] , and gamma -glutamyl 
transferase ( GGT ) observed in this subject were also reported as AEs. Total bilirubin 
remained within the normal range. Other clinical chemistry findings were unremarkable.  
More detailed infor mation on macitentan Phase 1 studies can be found in the IB 
[Macitentan IB ]. 
1.5.2.2 Phase 2 studies  
A Phase 2 dose -finding study was conducted over 8 weeks in 379 patients with mild to 
moderate essential hypertension. Four dose s of maciten tan (0.3 mg, 1 mg, 3 mg, and 
10 mg) and enalapril (20 mg) once daily were evaluated versus placebo. The primary efficacy endpoint of change from baseline to Week 8 in mean sitting diastolic blood 
pressure at trough (i.e., 24 h post -dose) was met. Macitentan was well tolerated across all 
4 dose levels. The overall frequency of AEs was similar to that observed in the placebo group. The numbers of patients with at least one serious adverse event (SAE) were equally distributed across groups. There w ere no deaths.  
Five cases of increased liver enzymes > 3 × ULN occurred in the macitentan groups, 
without obvious dose relationship (one, two , one, and one in the 0.3 mg, 1 mg, 3 mg, and 
10 mg dose groups, respectively). In 3 cases, there  were other plausi ble reasons for 
increased liver enzymes (pancreatic cancer, surgery with general anesthesia, and concomitant antibiotic therapy, respectively). Most of the episodes of liver enzyme 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 34/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
elevations resolved without sequelae within 2–3 weeks of observation. An episode of 
liver enzyme increase in a patient with pancreatic cancer resolved 48 days after surgery for pancreatic cancer.   
A double -blind, randomized, placebo- controlled, multi- center, parallel group Phase 2 
study to evaluate the efficacy and safety of a 10  mg dose of macitentan in 178 patients 
with idiopathic pulmonary fibrosis did not meet the  primary endpoint (change in forced 
vital capacity) . Overall, 10 mg macitentan was well tolerated with a similar safety profile 
in both treatment  groups. The incidenc e of treatment -emergent AEs was similar in both 
groups. Dyspnea, peripheral edema, anemia,  pneumonia and nausea occurred at a higher 
incidence in patients on macitentan than on placebo.  
An equal proportion of patients in the 2 treatment groups experienced SAEs or died 
during the study. The most frequently reported SAEs and causes of death were  all 
consequences of the underlying disease. Seven patients treated with macitentan had a 
decrease in hemoglobin levels to ≤ 10 g/dL at some point during the study  and the overall 
incidence of elevations in liver aminotransferases > 3 × ULN was similar to placebo 
(3.4% in the macitentan group versus 5.1% in the placebo group ).  
More detailed information on this macitentan Phase 2 study can be found in the  IB 
[Macitentan IB ]. 
1.5.2.3 Phase 3 study in patients with pulmonary arterial hypertension 
Efficacy in patients with WHO functional class  II-IV PAH was demonstrated with the 
long- term outc omes SERAPHIN study. T he trial demonstrated that macitentan 10  mg 
reduces the risk of morbidity or mortality in patients with symptomatic PAH, with a hazard ratio versus placebo of 0.547, 97.5% confidence inte rval 0.392–0.762, p < 0.0001. 
This represents a risk reduction of 45% [ Pulido 2013]. 
Treatment with macitentan was well tolerated. The number of AEs reported and patients discontinuing treatment due to AEs was similar across all groups. The overall incidence of elevations in liv er aminotransferases was similar to placebo (4.5%, 3.6%, and 3.4% 
incidence of ALT or AST > 3 ×  ULN in the placebo, macitentan 3 mg, and macitentan 10 
mg groups, respectively). In addition, no differences were observed between macitentan and placebo on fluid retention (edema). A decrease in hemoglobin – reported as an AE  – 
was observed more frequently on macitentan than placebo, with no difference in treatment discontinuation between groups. 
More detailed information  on the Phase 3 study in PAH  can be found  in the  IB 
[Macitentan IB ]. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 35/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
1.5.2.4 Summary of potential risks and risk management 
Nonclinical studies with macitentan did not identify important risks of likely relevance to 
humans except for teratogenicity, a class effect of E RAs. The protocol, therefore, 
includes stringent requirements for pregnancy testing and reliable methods of contraception for female patients of childbearing potential.  
In a Phase 1 study of macitentan in patients with chronic hepatic impairment, one patie nt 
being treated with macitentan experienced clinically relevant ALT/AST elevations although bilirubin remained in the normal range. In three  placebo -controlled studies, a 
higher percentage of patients treated with macitentan 10 mg had ALT > 3 × ULN compar ed to placebo. Although an independent review of all data by the Independent 
Liver Safety Data Review Board (ILSDRB)  concluded that there is no definite 
hepatotoxicity signal, precaution has been taken in this study to exclude subjects with severe hepatic impairment, as described in the Opsumit
® prescribing information , or 
unstable liver disease due to the poor prognosis. Therefore, subjects with  a Child -Pugh 
class C grading or Model for End- stage Liver Disease ( MELD ) score of ≥ 19 are 
excluded, as well as those with gastrointestinal or esophageal varic eal bleeding within 
3 months or transjugular intrahepatic portosystemic shunt ( TIPS ) within 6 months  of 
randomization, or in the opinion of the investigator the subject is too unstable to enter the 
study . In addition, subjects must not meet  the exclusion criteria of ALT/AST ≥  3 × ULN  
and total bilirubin ≥  3 mg/dL. The inclusion of patients with moderate hepatic 
impairment is considered justified in this study due to the unaltered  PK profile of 
macitentan between mild, moderate or severe hepatic impairment in the Phase 1 study described above, as well as a fixed rule for discontinuation of study drug in the event of 
liver aminotransferase elevations.  Monthly LFTs are mandat ory throughout the study and 
recommended up to 30 days after study treatment  discontinuation. Hepatic 
encephalopathy is frequent in patients with severe hepatic impairment and can lead to 
varying degrees  of reversible dementia. In order to ensure subjects are fully able to give 
informed consent, hepatic encephalopathy of Grade 2 and higher has been excluded.  
Macitentan treatment was associated with a dose- related reduction in hemoglobin levels. 
Therefore, p atients with hemoglobin < 100 g/L ar e excluded fro m the study. Furthermore, 
hemoglobin levels are monitored monthly throughout the study. 
Due to the vasodilator effect of macitentan, effects on BP  might occur. In patients with 
normal BP at baseline, there was a slightly higher incidence of AEs denoting hy potension 
with macitentan  than with placebo. Thus, patients with systolic blood pressure  (SBP)  
< 90 mmHg are excluded from this study. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 36/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
1.6 Purpose and rationale of the study 
Although PoPH is included in the WHO Group I Pulmonary Hypertension spectrum of 
diseases (PAH)  according to the updated guidelines for clinical classification of PH  
[Simmoneau 2013] , no targeted PAH therapy  has to date demonstrated efficacy in this 
patient population in a  randomized, controlled clinical trial. PoPH patients have been 
excluded from protocols in PAH due to the potential for altered drug metabolism as a consequence of the underlying hepatic disease. However, as PoPH is essentially pre-capillary PH, these patients are managed on a day -to-day basis with commercially 
available PAH medications  including ERAs . Use of these pulmonary vasodilators  has 
been mostly based on evidence from single -center, open -label experience.   
In the Phase 3 AC -055-302/ SERAPHIN study,  macitentan demonstrated eff icacy in PAH 
by improving long- term clinical outcomes, functional status and exercise capacity . In 
addition, incidences of ALT/AST elevations > 3 ×  ULN were similar to placebo . Phase 1 
data in chronic hepatic impairment showed no clinically relevant change  in the PK of 
macitentan and its metabolites in varying grades of liver disease severity  [Macitentan IB ].  
Therefore, it is believed that macitentan could be an efficacious treatment for PoPH with a safety and tolerability profile unaffected by the underlying hepatic disease.   
The aim of this study is to investigate the efficacy of macitentan on cardiopulmonary 
hemodynamics as well as the safety and tolerabilit y in patients with PoPH in a 
randomized, placebo- controlled study setting.  
2 STUDY OBJECTIVES 
2.1 Primary objective  
• To evaluate the effect of macitentan on PVR as compared to placebo in patients with 
PoPH.  
2.2 Secondary objectives  
• To evaluate the effect of macitentan as compared to placebo on cardio-pulmonary hemodynamics,  hepatic portal vein pressure, disease severity, and exercise capacity in 
patients with PoPH.  
• To evaluate the safety and tolerability of macitentan in patients with PoPH  
• To evaluate the PK of macitentan and its active metabolite ACT -132577 in patients  
with PoPH  (PK substudy).  
 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 37/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
3 OVERALL STUDY DESIGN AND PLAN  
3.1 Study design  
This study is designed as a randomized, double- blind, placebo-controlled, prospective, 
multicenter, parallel group Phase 4 study  assessing the efficacy and safety of macitentan 
in PoPH. 
Approximately 84 adult subjects  with PoPH  will be randomized (1:1) to receive either 
maci tentan 10 mg, or matching placebo, once daily orally . Subject allocation to treatment 
groups will be stratified by background PAH therapy receipt  (yes/no) to ensure balan ce 
within this subgroup. Stratification by region  of enrollment will also be performed as  the 
number of  enrolled subjects per cent er is expected to be low and variation in total subject 
numbers will exist on a country -to-country level. Attrition rate is ex pected to be 10%, 
leaving 76 evaluable patients at Week 12. Subjects must have confirmed diagnosis of PoPH with a PVR of ≥ 4 Wood Units (WU ) 
(≥ 320 dyn.s.cm -5) at enrollment but not have severe hepatic impairment (defined as 
Child -Pugh Class C or MELD scor e ≥ 19). Subjects must have 6-minute walk distance 
(6MWD) ≥ 50 m at enrollment but may be in any WHO functional class . 
The study will be conducted in approximately 45 sites in 7 countries. Randomization will 
proceed until the required number of subjects ha s been reached. It will be competitive 
across participating sites. Actelion may wish to replace sites with no subject enrollment.  
The study consists of the following study periods: Screening Period  commences from signature of the Informed Consent Form (ICF ) and 
ends with subject randomization (up to 28 days  after signed informed consent). 
Double -Blind Treatment Period  starts immediately after randomization with the first  
dose of double-blind study treatment at the end of Visit 2 (Day 1 of study) and ends wi th 
End of Treatment (double-blind) (EOT -DB) on the day of the last dose of double-blind 
study treatment ( scheduled Day 84, Week 12 , or earlier in case of premature 
discontinuation of double-blind study treatment ).  
Open -Label Treatment P eriod  starts immediately after EOT -DB (for patients who 
reach Week 12 of double-blind study treatment)  with the first  dose of open- label study 
treatment  at the end of Visit 5 and ends with End of Treatment  (open- label)  (EOT -OL) on 
the day of the last dose of open- label study treatment  (scheduled Day 168 , Week 24, or 
earlier in case of premature discontinuation of open- label study treatment).   
Safety Follow- up Period  starts immediately after the last dose of study treatment  
(double-blind study treatment  or open- label study tre atment ) and ends with the E nd of 
Study (EOS) 30 to 33 days after the last dose of study treatment. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 38/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
EOS  must occur in any patient discontinuing either double -blind or open- label study 
treatment  prematurely and having completed the Safety follow-up period. 
Study Duration 
Subject participation in the study will be maximum 33 w eeks (up to 28 days Screening 
+ 24 weeks ’ treatment + 30 days safety follow up) . The overall study design is depicted 
in Figure 1.  
Figure 1 Study design  
 
EOT -DB = end of treatment  (double -blind) ; EOT -OL = end of treatment  (open -label); EOS = end of study . 
3.2 Study design rationale 
A placebo -controlled trial conducted in a randomized, double -blind fashion provides the 
most definite and rigorous method of evaluating the efficacy and safety of a medical 
treatment.  
The present study aims at assessing whether macitentan improves hemodynamic variables and whether this improvement translates into symptomatic and clinical improvement in PoPH subjects. Subjects will receive macitentan or placebo for 12 weeks 
followed by 12 weeks of open- label macitentan treatment and then a 30- day safety 
follow-up.  
The 12- week double -blind treatment period is selected because it is considered to be 
adeq uate to observe the anticipated treatment effect on the primary endpoint of change in 
PVR , but short enough to minimize risk of randomization to placebo. The risk of bias 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 39/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
introduction from patients initiating add -on therapy is deemed relatively low in this  
timeframe and the number of missing assessments due to premature study discontinuation 
is also expected to be minimized. Additionally, in studies involving hemodynamics and exercise capacity, variability and placebo effect are of sufficient magnitude to j ustify the 
inclusion of a placebo control group [ Wright 2009]. Risk of exposure to placebo is also 
minimized by permitting into the study subjects already receiving stable background oral PDE5i, sGC stimulator, or inhaled prostanoid PAH therapy. Once in the open- label 
period patients may also receive i.v. or subcutaneous ( s.c.) prostanoid PAH -therapy at the 
investigator ’s discretion. 
Treatment with ERAs has been associated with increased incidence of edema, anemia and/or decreased hemoglobin as well as LFT abnormali ties. From 3  placebo -controlled 
studies with macitentan, no significant imbalance in L FT elevations was observed across 
macitentan treatment groups (any dose) and placebo. However, due to underlying liver disease in PoPH, liver safety events are likely to occur in this population and a placebo 
arm is the only way to show quantitatively  whether there is a likely association of liver 
abnormalities with  the use of the study treatment. 
The 12-week open -label treat ment period is intended to offe r all patients  the opportunity  
to receive active study treatment  and allows time for organizing appropriate treatment 
after the study . In addition, the open- label phase is being used to perform a substudy in a 
minimum of  20 participating subjec ts in order to obtain information on the PK of 
macitentan in PoPH . 
3.3 Study Committees  
A Steering Committee has been appointed by Actelion to design the protocol, oversee the conduct of the study, evaluate the results and support publicati ons. The committee is 
governed by a steering committee charter.  
An Independent Liver Safety Data Review Board (ILSDRB, an external expert committee of hepatologists) provides ongoing assessment and advice regarding serious hepatic adverse events of special interest that require further evaluation during the study 
(as per ILSDRB charter).  
4 SUBJECT POPULATION 
4.1 Subject population description 
Subjects enrolled will be male or female aged 18  years  and over with a confirmed 
diagnosis of symptomatic PoPH  and a baseline PVR of ≥ 4 WU ( ≥ 320 dyn.s.cm-5), in 
any WHO  functional class and capable of performing a 6MWT. Subjects may be 
PAH- treatment naïve or receiving background PDE5i , sGC stimulators,  or inhaled 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 40/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
prostanoid therapy. Subjects must not have severe hepatic impairment, as defined by 
Child -Pugh class C liver disease or a MELD score ≥ 19.  
A minimum of 8 4 subjects will be enrolled. An assumed attrition rate of 10% will leave 
76 evaluable patients at Week 12 for the primary analysis.   
4.2 Rationale for the selection of the study population 
The primary objective of the study is to demonstrate a reduction in PVR versus baseline 
with macitentan treatment as compared to placebo. A subset of PoPH patients with 
elevated PVR  (≥ 4 WU or 3 20 dyn.s.cm-5) has been selected to im prove the chance of 
observing the planned placebo- corrected reduction of 27% from baseline. No restriction 
on WHO functional class an d a minimum 6MWD of ≥ 50 m will permit patients with 
severely symptomatic PH  to be enrolled, as macitentan is expected to s how a treatment 
effect on PVR in these patients as well.  
As PoPH is managed clinically with PAH -targeted therapy, subjects receiving 
concomitant background PDE5i, sGC stimulators, or inhaled prostacyclin therapy at a 
stable dose may be enrolled. This is al so to mitigate the risk of exposure to placebo 
during the study. S ubjects receiving strong vasodilator therapy at baseline ( i.v. or s.c. 
prostanoids) are excluded.   
Subjects with severe hepatic impairment (defined here as Child -Pugh C or MELD sc ore 
≥ 19) are not permitted to be enrolled due to their poor prognosis, as are those whose 
liver disease is unstable in the opinion of the investigator. Such patients have an increased risk of premature discontinuation, transplantation or death during the 
double- blind phase of the study which would impact the study ’s ability to achieve its 
primary objective. Other indicators of severe liver disease and/or poor prognosis  include 
gastrointestinal and e sophageal varic eal bleeding, as well as total serum biliru bin  
≥ 3 mg/dL.  
As there is limited  data o n macitentan in pediatric PAH, subjects under the age of 
18 years  are excluded.  
4.3 Inclusion criteria 
For inclusion in the study, all of the following inclusion criteria must be fulfilled. It is not permitted to waive any of the criteria for any subject:  
1. Signed informed consent prior to any study-mandated procedure  
2. Male or female ≥  18 years of age with symptomatic PoPH: 
• Documented diagnosis of portal hypertension  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 41/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• PAH by right heart catheterization at screening:  
− mPAP ≥ 25 mmHg  
− PAWP or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg 
3. PVR ≥ 4 W U or ≥ 320 dyn.s.cm-5 at screening2 
4. 6MWD ≥ 50 m at screening 
5. Women of childbearing potential must:  
• Have a negative serum pregnancy test during screening and a negative urine 
pregnancy test on prior to randomization on Day 1, and 
• Agree to use reliable methods of contraception [ see Section  4.5] from 
screening up to 30 days after study treatment discontinuation, and 
• Agree to perform monthly pregnancy te sts up to 30 days after study treatment 
discontinuation. 
4.4 Exclusion criteria 
Subjects must not meet  any of the following exclusion criteria. It is not permitted to 
waive any of the criteria for any subject:  
1. PAH due to any other condition than portal hypertension 
2. Severe hepatic impairment, as defined by Child -Pugh Class C liver disease or MELD 
score ≥ 19  
3. Unstable liver disease (in the opinion of the investigator) 
4. History of TIPS  within  6 months prior to randomization 
5. Documented severe obstructive or restrictive lung disease (in the opinion of the investigator)  
6. Documented pulmonary veno- occlusive disease  
7. Systolic blood pressure (SBP) < 90 mmHg at Screening 
8. Body weight < 40 kg at Screening  
9. Patients undergoing dialysis 
                                                 
  
2 Cardiac output measured by thermodilution technique only. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 42/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
10. Initiation of diuretics or beta blockers w ithin 1 week prior to baseline RHC or  
patients on oral diuretics or beta blockers in whom the dose has not been stable for at 
least 1  week prior to baseline RHC 
11. Hemoglobin < 100 g/L at Screening 
12. Serum AST and/or ALT ≥ 3 × ULN at Screening  
13. Bilirubin ≥  3 mg/dL at Screening  
14. Grades 2, 3, or 4 hepatic encephalopathy  
15. History of liver transplantation  
16. Documented  hepatocellular carcinoma  
17. Documented  schistosomiasis infection  
18. Gastrointestinal bleeding or esophageal variceal  bleeding  < 3 months prior to 
randomization 
19. Recently started  (< 3 months prior to randomization) or planned cardio -pulmonary 
rehabilitation program based on exercise 
20. Treatment with calcium channel blockers,  an endothelin receptor antagonist ( ERA ), 
i.v./s.c. or oral prostanoids within 3 months prior to randomization 
21. Initiation, change in dose or discontinuation of PDE5i  or soluble guanylate cyclase 
stimulator within 3 months prior to randomization 
22. Treatment with interferon within  3 months prior to randomization 
23. Treatment with any investigational drug within 3 months prior to randomization  
24. Treatment with strong cytochrome P450 (CYP) 3A4 inducers ( e.g., carbamazepine, 
rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John’ s 
wort) within 4 weeks prior to randomization 
25. Treatment with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, boceprevir, telaprevir, saquinavir, lopinavir , fosamprenavir, darunavir, tiprana vir, atazanavir, 
nelfinavir, amprenavir, i ndinavir , and paritaprevir ) within 4 weeks prior to 
randomization 
26. Known hypersensitivity to macitentan  or its excipients or drugs of the same class  
27. Pregnancy , breastfeeding, or intention to become pregnant during the study 
28. Known concomitant life- threatening disease with a life expectancy of < 6 months  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 43/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
29. Any known factor or disease that might interfere with treatment compliance, study 
conduct, or interpretation of results 
30. Suspected or known current drug or alcohol abuse. 
4.5 Reliable contraception for women of childbearing potential 
4.5.1 Definition of woman of childbearing potential  
A woman is considered to be of childbearing potential unless she meets at least one of the following criteria:  
• Previous bilateral salpingo -oophorect omy or hysterectomy.  
• Premature ovarian failure confirmed by a specialist.  
• Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis. 
• Post- menopausal, defined as 12 consecutive months with no menses without an 
alternative medical cause
 (ICH M3 definition). 
4.5.2 Europe  and Latin America  
The use of at least one of the following methods is regarded as reliable contraception: 
1. Oral, implantable, transdermal, or injectable hormonal contraceptives or intrauterine 
devices (IUD), or  
2. True abstinence from intercourse with a male partner  only when this is in line with 
the preferred lifestyle of t he patient, or  
3. Permanent female sterilization ( tubal occlusion/ ligation at least 6 weeks prior to 
screening ), or 
4. Sterilization of the male partner , with documented post -vasectomy  confirmation of  
the absence of sperm in the ejaculate.  
Rhythm methods, use of a condom by the male partner alone, use of a female condom or 
diaphragm alone are not considered acceptable methods of contraception for this study. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 44/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
4.5.3 North America  
The use of one of the following options is regarded as reliable contraception: 
Option 1   Option 2   Option 3   Option 4  
One method from 
this list:   One method from 
this list:   One method from 
this list:   One method from 
this list:  
Standard intrauterine   Estrogen and   Diaphragm with   Partner ’s vasectomy  
device (IUD) 
(Copper T380A IUD)   progesterone oral 
contraceptives ( “the   spermicide  
Cervical cap with   PLUS one method 
from this list:  
Intrauterine system   Pill”)  spermicide   Male condom  
(LNg 20IUS: 
progesterone I US)  Estrogen and 
progesterone   PLUS one method 
from this list:   Diaphragm with 
spermicide  
Progesterone implant   transdermal patch   Male condom   Cervical cap with  
Tubal sterilization   Vaginal ring     spermicide  
  Progesterone 
injection     Estrogen and  
progesterone oral  
  PLUS one method 
from this list:     contraceptives ( “the 
pill”) 
  Male condom  
Diaphragm with 
spermicide  
Cervical cap with 
spermicide     Estrogen and 
progesterone transdermal patch  
Vaginal ring  
Progesterone  
 
      injection  
IUD, int rauterine device; IUS, intrauterine system.  
4.6 Medical history 
Relevant medical history, as defined below, must be recorded in the electronic Case 
Report Form (e CRF ):  
• Chronic medical conditions and new acute medical conditions within the past 6 months (e.g., anemia, hepatitis C infection, HIV infection, obstructive or restrictive 
lung disease, hypertension, renal disease)  
• Complications or symptoms associated with the PAH (e.g., right heart failure, peripheral edema)  or portal hypertension (e.g., liver decompensation) 
• Cause of portal hypertension (e.g., cirrhosis, hepatitis infection, thrombosis) 
• History  of TIPS and date of procedure 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 45/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• History  of spontaneous or congenital porto-systemic shunts 
• History of esophageal varic es or gastrointestinal bleeding , ascites, h epatic 
encephalopathy (including Grade) 
• History of alcoholism and/or drug abuse 
• Any previous life-threatening conditions, including date (e.g., myocardial infarction). 
5 TREATMENTS 
5.1 Study treatment  
Study treatment in this study includes double -blind as well a s open -label study treatment. 
Double- blind treatment comprises investigational treatment (i.e., macitentan 10 mg ) or 
matching placebo administered orally once daily. Open -label study treatment  consists of 
open- label macitentan 10 mg and is also administere d orally once daily. 
5.1.1 Investigational treatment: description and rationale 
The investigational treatment is macitentan 10 mg and is administered orally once daily , 
in accordance with the Opsumit® prescribing information . 
5.1.2 Matching placebo: description and ra tionale 
Matching placebo is administered orally and also once daily . Rationale for the use of a 
placebo arm is provided in Section 3.1. 
5.1.3 Study treatment administration  
The first  administration of study treatment will take place at site during the 
randomization visit (Visit 2) , and only after successful completion of the ICF procedure 
and all screening/randomization assessments.  At all subsequent visits  (apart from PK 
substudy) , study treatment  must only be taken after all study procedures have been 
performed . 
At home, one tablet (macitentan 10 mg or matching placebo) must be taken orally every 
morning irrespective of food intake. If a dose is missed, take the next dose at the next scheduled time point (i.e., do not take one table t in the evening and then one table the 
next morning). Two tablets must never be taken on the same day. 
5.1.4 Treatment assignment  
Eligible subjects will be randomized in a 1:1 ratio to either macitentan 10 mg or matching 
placebo. Treatment allocation will be str atified based on receipt of background PAH 
therapy (Yes/No) and by region (Europe/ North America/ Latin America ). 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 46/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
At Visit 1 (Screening), all screened subjects will be assigned a study -specific subject 
number by the Interactive Voice/Web Response System (IxR S) provider. Note: In case of 
re-screening, the original number will also be used the second time. 
At Visit 2 (Randomization), after having confirmed the eligibility of the subject and prior 
to the start of study treatment, the investigator/delegate will contact the IxRS to 
randomize the subject. The IxRS will assign a randomization number to the subject, and 
assign the treatment bottle  number which matches the treatment arm assigned by the 
randomization list to the randomization number. The bottle with this unique number will 
then be dispensed to the subject and the first dose administered. 
The randomization list is generated by an independent Contract Research Organization 
(CRO)  using SAS version 9.3, and kept strictly confidential. 
5.1.5 Blinding  
The fi rst part of t his study will be performed in a double -blind fashion. The investigator 
and study staff, the subjects, the monitors, Actelion and CRO  staff involved in the 
conduct of the study will remain blinded to the treatment until study closure.  
Althoug h the second part of the study will be performed in an open- label manner, all 
subjects and study -related staff will r emain blinded as to the patient ’s original 
randomization group. Until the time of unblinding for final data analysis, the randomization list is kept strictly 
confidential, and accessib le only to authorized persons  who are not involved in the 
conduct of the study.  
The investigational treatment and its matching placebo  are indistinguishable and all 
subject kits will be packaged in the same way . 
5.1.6 Unblinding  
5.1.6.1 Unblinding for final analyses 
Full randomization information will be made available for data analysis only after 
database closure in accordance with Actelion Standard O perating P rocedures ( SOPs ). 
5.1.6.2 Unblinding for SUSARs  
When a s uspected unexpect ed serious adverse reaction ( SUSAR ) occurs for a subject 
participating in the study, Actelion Global Drug Safety will request the unblinding of the treatment assignment. The randomization code will not be communicated to the site staff or to the Actelion study team; unblinded SUSAR information will be anonymized and provided to Actelion Global Drug Safety, respective health authorities and IRBs/IECs only. SUSARs will be reported to investigators in a blinded fashion. 

Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 47/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
5.1.6.3 Emergency procedure for unblinding  
The i nvestigator, study staff and sponsor staff must remain blinded to the subject ’s 
treatment assignment. The identity of the study treatment may be revealed only if the 
subject experiences a medical event, the management of which would require knowledge of th e blinded treatment assignment.  The occurrence of OLT during the double -blind 
treatment period could constitute such an event. In this case, the investigator can receive 
the unblinded randomization code for study treatment allocation through the I xRS. In 
these situations, the decision to unblind resides solely with the investigator. Whenever it 
is possible and if it does not interfere with (or does not delay) any decision in the best interest of the subject, the investigator is invited to discuss the intend ed code break with 
Actelion.  
The occurrence of any code break during the study must be clearly justified and explained by the investigator. In all cases, Actelion must be informed as soon as possible before or after the code break.  
The circumstances leadin g to the code break must be documented in the subject ’s site file 
and e CRF.  
Refer to the I xRS manual for complete information regarding the I xRS procedures for 
randomization, study treatment assignment, and unblinding.  
5.1.7 Study treatment supply  
Actelion will supply all study treatments to the site according to the local regulations. 
Manufacture, labeling, packaging and supply of study treatments will be  conducted 
according to Good Manufacturing Practice (GMP), Good Clinical Practice ( GCP ) and 
any local or nat ional regulatory requirements . 
All treatment supplies are to be used only in accordance with this protocol, and not for 
any other purpose. 
5.1.7.1 Study treatment packaging and labeling 
5.1.7.1.1 Study treatment packaging 
Study treatment is provided as tablets and supplied in childproof bottles  containing 
36 tablets . 
5.1.7.1.2 Study treatment labeling 
Study treatment is labeled to comply with the applicable laws and regulations of the 
countries in which the study sites are located. Each medication bottle has a label with a tear-off part specifying the study protocol number, the packaging batch number, and the 
bottle number. When the study treatment is given to the subject, this tear -off part must be 
removed and attached to the Study Treatment Dispensing Log.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 48/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
5.1.7.2 Study treatment distribution and storage  
Treatment supplies must be kept in an appropriate, secure area and stored according to 
the conditions specified on the medication labels. The investigator is responsible for the 
safe and proper handling and storage at the i nvestigational site . 
5.1.7.2.1  Study treatment distribution  
The study centers will be supplied with study treatment according to the centers ’ needs, 
depending on the rate of subject enrollment. Each center will have an individual stock of  
study treatment, which will be re -supplied continuously as soon as a predefined minimum 
level of study treatment has been reached.  
5.1.7.2.2 Study treatment storage  
Study treatment must be kept in a locked room or a locked cupboard in a restricted access  
room, which can be accessed only by the pharmacist,  the investigator, or another duly  
designated person as specified on the delegation of authority (DoA) form.  
The subject must be educated on the proper study treatment storage conditions at home.  The study treatment must be stored below 30 °C (86  °F) and must be protected from  
moisture. Unopened, sealed study medication bottles may be stored in refrigerators  
(above + 2 °C [36 °F]). Storage below + 2 °C / 36 °F (e.g., in the freezer) is not  permitted. 
Opened bottles must not be stored in the refrigerator.  A temperature log must be maintained and temperature control should occur at least on a  
weekly basis at the site. Actelion will provide a temperature log; however, the use of the  
log is not mandatory if the site has an acceptable means of recording the temp erature.  
Any temperature recording system routinely used at site is acceptable as long as all  
required information is included and certification of calibration is provided. If the  
temperature is captured electronically, a print -out should be made available  to the  CRA 
during each on- site visit for filing in the Investigator Site File (ISF) .  
In case a deviation from the defined temperature range is identified by the study center,  
the deviation must be reported to the CRA , preferably in writing and with supporting  
documentation (e.g., copy of the temperature log showing data for all excursion days).  
The CRA should immediately contact Actelion for further advice. The affected study  
treatment will not be used (e.g., it will be segregated physically at the study center) until  
confirmation from Actelion is obtained that its use is safe. In case the temperature  
deviation is outside of the acceptable limit, the study treatment is kept segregated at the 
study center and returned to Actelion following internal study tr eatment return processes.  
New study treatment supplies will be provided to the study center.  
Temperature deviations correspondence must be kept in the I SF.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 49/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
5.1.7.3 Study treatment dispensing  
Study treatment can only be dispensed upon written prescription by an authorized study  
physician listed on the DoA form.  
The subjects will receive sufficient study treatment to cover the period up to the next 
scheduled visit. Subjects are asked to return all used, partially used and  unused study 
treatment bottles  at each vis it. The protocol -mandated study treatment dispensing/return 
procedures may not be alter ed without prior written approval from Actelion. An accurate 
record of the date and amount of study treatment dispensed to each subject must be available for inspection at any time.  
Once a subject has been randomized and study treatment assigned, the corresponding bottle must not be used for another subject. If a subject has been dispensed a bottle in error (one that has not been allocated yet to another subject), the IxRS helpdesk must  
immediately be contacted.  
At the time study treatment is distributed, the subject should be educated on the proper  
storage conditions at home [ see Section 5.1.7.2.2].  
5.1.7.4 Study treatment return and destruction  
The site must record the amount of study treatment received, dispensed, used, lost and 
returned during the study. On an ongoing basis and/or on termination of the study, the monitor will collect used and 
unused subject kits, which will be sent to the warehouse, where Actelion or a deputy will check treatment reconciliation. In certain circumstances, used and unused treatment containers may be destroyed at the site once treatment accountability is finalized and has been checked by the CRA , and written permission for destruction has been obtained from 
Actelion.  
5.1.8 Compliance with study treatment  
Study treatment accountability must be performed by the study staff on the day of the visit and before providing further study treatment, in order to ensure that the subje ct is 
compliant with study requirements. Study treatment accountability is recorded in the eCRF  and checked by the monitor during site visits and at the end of the study. An 
accurate record of the date and amount of study treatment dispensed to each subjec t must 
be available for inspection at any time.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 50/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Prior to each new dispensation, the visit compliance must be evaluated by the site staff, 
based on study treatment accountability, as per formula below: 
Complianc e = [(number of tablets provided to subject - number of tablets returned) / 
Total number of Tablets that should have been taken during the period]  
× 100 
The site staff should discuss any compliance issue with the subject and re -educate 
him/her on correct administration of study treatment. Det ails of such discussion must be 
documented in the subject’ s file.  
If the compliance w ith study treatment intake is <  80% or >  120%, permanent 
discontinuation of study treatment may be considered after consultation with Actelion.  5.1.9 Study treatment dose adjustments and interruptions  
Study treatment may be temporarily interrupted in response to an AE, a diagnostic or 
therapeutic procedure, a laboratory abnormality, or for administrative reasons. Study- specific criteria for interruption of study treatment are described  in Section  5.1.11. 
If study treatment intake is interrupted by the subject for any reason, she/he must immediately inform the investigator.  
Interruptions of study treatment should be kept as short as possible. If treatment is 
stopped for more than 14  days, reintroduction is not permitted and treatment must be 
permanently discontinued [ see Section  5.1.11].  
Study treatment dose errors /interruptions must be recorded in t he eCRF.  
5.1.10 Premature discontinuation of study treatment  
The decision to prematurely discontinue study treatment may be made by the subject, the investigator or Actelion.  
A subject has the right to prematurely discontinue study treatment at any time by withdr awal from treatment only or by withdrawal from treatment and  any further 
participation in the study.  
The investigator should discontinue study treatment for a given subject if, on balance, he/she believes that continued administration would be contrary to the best interests of the subject.  
Premature discontinuation of study treatment may also result from a decision by Actelion, e.g., in case of premature termination or suspension of the study [see Section  9.3].  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 51/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Study treatment may be discontinued in response to an AE, lack of efficacy (including 
disease progression, treatment failure, worsening of patient condition), a protocol 
deviation (including eligibility failure, non -compliance with study requirements, such as 
non-compliance with study treatment intake or visit attendance), or if the subject is lost to 
follow- up. Study -specific criteria for discontinuation of study treatment are described in 
Section  5.1.11. 
The mai n reason and whether discontinuation of study treatment is the decision of the 
subject, the investigator or Actelion must be documented in the e CRF.  
A subject who prematurely discontinues study treatment is NOT  considered as withdrawn 
from the study and will be followed up until EOS or 30 days  after study treatment 
discontinuation, provided that the subject ’s consent for this limited participation in the 
study has not been withdrawn. 
A subject who prematurely discontinues study treatment and withdraws consent to participate in any further study assessments is considered as withdrawn from the study. Subjects who die or are lost to follow -up are also considered as withdrawn from the 
study. Withdrawal from the study and follow-up medical care of subjects withdrawn from the study is described in Sections 9.2 and 9.4, respectively.  
5.1.11 Study -specific criteria for interruption / premature discontinuation of study 
treatment  
A) Preg nancy  
If a female subject becomes pregnant while on study treatment, study treatment must be 
discontinued immediately, and a Pregnancy Form must be completed [ see Section 10.3].  
B) Liver aminotransferases abnorm alities  
Interruption of study treatment 
Study treatment  must be interrupted in the following cases: 
• Asymptomatic increase in a minotransferases (i.e., ALT and/or AST) ≥  3 and  
< 8 × ULN.  
In such a case, perform a re- test of aminotransferases (ALT and AST), total and direct 
bilirubin, and alkaline phosphatase within one week. If AST and/or ALT elevation is confirmed, continue to monitor aminotransferases, total and direct bilirubin, and alkaline phosphatase levels weekly until values return to pre -treatment levels or within normal 
ranges. If the aminotransferase values return to pre- treatment levels or within normal 
ranges, reintrod uction of study treatment can be considered. Interruptions must be for less 
than 2 consecutive weeks; longer interruptions must lead to permanent discontinuation of study treatment.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 52/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Reintroduction of study treatment after treatment interruption should onl y be considered 
if the potential benefits of treatment with macitentan outweigh the potential risks and 
when liver aminotransferase values are within pre- treatment levels or within normal 
ranges. The advice of a hepatologist is recommended.  
Liver aminotran sferase levels must then be checked within 3 days after reintroduction, 
then again after a further 2 weeks and thereafter according to the recommendations above (i.e., at monthly intervals). 
Permanent discontinuation of study treatment 
Study treatment must be stopped and its reintroduction is not to be considered in the 
following cases: 
• Aminotransferases ≥  8 × ULN  
• Aminotransferases ≥  3 × ULN and associated with new or worsening  clinical 
symptoms of liver injury, e.g., nausea, vomiting, fever, abdominal pain, jaundice, 
unusual lethargy or fatigue, flu like syndrome (arthralgia, myalgia, fever) 
• Aminotransferases ≥  3 × ULN associated with total bilirubin ≥  2 × ULN  and 
increased as compared to baseline  
In such cases, aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must be monitored weekly after study treatment  discontinuation until values return 
to pre- treatment levels or within normal ranges.  
Other diagnoses (e.g., viral hepatitis, mononucleosis, toxoplasmosis, cytomegalovirus ,) 
and/or etiologies (e.g., acetaminophen- related liver toxicity) should be considered and 
ruled out by performing the appropriate tests. 
All liver aminotransferases abnormalities leading to study treatment  interruption or 
discontinuation must be recorded as AE s [see Section 10].  
An ILSDRB  (an external expert committee of hepatologists) provides ongoing 
assessment and advice regarding any hepatic events that require further evaluation during 
the study.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 53/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
C) Hemoglobin abnormalities  
In case of hemoglobin decrease from baseline* of > 20 g/L, a retest must be performed 
within 10 days, with additional laboratory evaluations that may include, but are not limited to, any of the following:  
• Red blood cell cellular indices (mea n corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration), peripheral blood smear, reticulocyte count, iron status (iron level, serum ferritin, total iron binding capacity, transferrin saturation), lactate dehydrogenase,  indirect bilirubin.  
Study treatment  should be temporarily interrupted if clinically mandated based on the 
investigator ’s judgment, or in any of the following situations: 
− A decrease in hemoglobin to < 80 g/L (< 4.9 mmol/L),  
− A decrease in hemoglobin from baseline* of > 50 g/L,  
− The need for transfusion.  
Reintroduction of study treatment  may be considered if hemoglobin recovery, defined as 
a return of hemoglobin above the lower limit of the normal range or if it returns to a value close to that at baseline.   
Interruption of study treatment must not last longer than 2 consecutive weeks; longer 
interruption must lead to permanent discontinuation of study treatment. 
*Baseline hemoglobin: last value obtained prior to first intake of double -blind study 
treatment.  
D) Child -Pugh classification or MELD Score worsening 
If a subject is assessed as being Chil d-Pugh class C of liver disease  or MELD Score  
≥ 19 at EOT -DB then study treatment  must be permanently discontinued and the 30 -day 
Safety follow -up is to be performed. The subject must not initiate open- label treatment.  
E) Start of a  PAH specific therapy  / strong CYP3A inducer / investigational drug 
Double- blind study treatment must be permanently discontinued if  escalation of  
PAH- specific therapy is required (e.g., other ERAs, i.v./s.c. prostanoids ), strong CYP3A4 
inducers and/or any other investigational treatments are started during  the double -blind 
treatment period .  
Open -label study treatment must only be discontinued in the open- label period if an ERA, 
strong CYP3A4 inducer , and/or any other investigational treatments is started. I.v./s.c. 
prostanoids are permitted in the open- label period at the investigator ’s discretion. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 54/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
F) Orthotopic Liver transplantation   
If a subject undergoes OLT during the double -blind tre atment phase, they must stop all 
study treatment at the earliest convenience and undergo EOS after 30 days ’ safety follow 
up.  
If a subject undergoes OLT during the open- label treatment phase, continue d treatment  
with OL study medication is permitted until Week 24 (EOT -OL), after which  the 
30 days ’ safety follow up should be performed. 
5.2 Previous and concomitant therapy 
5.2.1 Definitions  
A previous therapy is any treatment for which the end date is prior to the start of study 
(i.e., date of informed consent ). 
A concomitant therapy is any treatment that is either initiated or ongoing during  
Screening,  after Randomization, or up to 30 days after the end of study treatment.  
5.2.2 Reporting of previous/concomitant therapy in the CRF 
Any previous treatment for PAH / right  heart failure (including diuretics) and/or portal 
hypertension (including beta blockers, hepatitis C  medications) that has been 
discontinued within  3 months prior to randomization must be recorded in the eCRF. 
Generic name, route, start/end date of administration (as well as whether it was ongoing at start of study treatment and/or EOS) and dose will be collected. Any change in dose or route of administration will be captured on the log by completing a new line.  
All medications (including dietary supplements,  traditional and alternative medicines,  
i.e., plant -, animal -, or mineral -based medicines) taken between Screening visit and EOS 
are to be recorded on the concomitant medications page of the eCRF. Generic name, start/end dates of administration (as well as  whether it was ongoing at start of treatment 
and/or EOS), route, dose, and indication will be recorded in the eCRF.  
Hormonal contraceptives will be recorded on the contraception page of the eCRF.  5.2.3 Allowed concomitant therapy  
Oral PDE5i, inhaled prostacyc lin analogues, soluble guanylate cyclase  (sGC) stimulator  
are allowed if present for at least 3 months prior to randomization at a stable dose ( which 
must remain unchanged during the double -blind treatment period unless the patient 
experiences worsening of  PAH).   
Treatment with oral diuretics is allowed if ongoing at a stable dose for at least 1 week 
prior to baseline right heart catheterization; the dose may be optimized during the 
treatment period.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 55/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Beta blockers are allowed if present for at least 1 week prior to baseline right heart 
catheterization  at a stable dose (which should remain unchanged during the study). If 
discontinuation of beta blockers occurs during the study the patient should complete the 
study as scheduled.  
During the open- label period, i.v. and s.c. prostanoid therapy (e.g., epoprostenol, 
treprostinil) is permitted at any  time.  
The following antiviral hepatitis C medications are permitted: simeprevir, sofosbuvir, 
daclatasvir, ombitasvir, dasabuvir, ledipasvir, etravirine, raltegravir, ma raviroc, and 
ribavirin. 
5.2.4 Forbidden concomitant therapy  
• ERAs (e.g., bosentan, ambrisentan) 
• During the double -blind period, i.v./s.c. and oral prostanoid therapy  
(e.g.,  epoprostenol, treprostinil) is forbidden  
• Calcium channel blockers 
• Strong CYP3A4 inducers (e.g., carbamazepine, rifampin, rifampicin, rifabutin, 
rifapentin, phenobarbital, phenytoin, and St. John’ s wort)  
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, 
clarithromycin, telithromycin, nefazodone, ritonavir, lopinavir , fos amprenavir, 
darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, i ndinavir, boceprevir, 
telaprevir, paritaprevir , and saquinavir)  
• Treatment with interferon  
• Any other investigational drug. 
6 STUDY ENDPOINTS 
6.1 Efficacy endpoints 
6.1.1 Double -blind treatment peri od 
Baseline is the last assessment prior to initiation of double -blind treatment.  
6.1.1.1 Primary efficacy endpoint  
The primary efficacy endpoint is r elative change from baseline to Week 12 in PVR .  
A geometric mean in the active group showing a reduction of at least 20% in PVR when 
compared to the placebo geometric mean is  considered clinically relevant in this patient 
population. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 56/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
6.1.1.2 Secondary efficacy endpoints  
• Change from B aseline to Week 12 in mean right atrial pressure (mRAP), mPAP, 
cardiac index (CI), total pulm onary resistance (TPR) , and mixed venous oxygen 
saturation (SVO 2), all measured at rest  
• Change from B aseline to Week 12 in 6MWD 
• Change from B aseline to Week 12 in WHO functional class   
• Change from Baseline to Week 12 in NT -proBNP . 
6.1.1.3 Other efficacy endpoints  
• Change from Baseline to Week 12 in hepatic venous pressure gradient ( HVPG ) 
• Change from Baseline to Week 12 in Borg dyspnea index. 
6.1.2 Macitentan -treatment period  
Macitentan Baseline is the last assessment prior to initiation of macitentan treatment 
(i.e., double- blind baseline for subjects randomized to receive blinded macitentan 10 mg, 
or Week 12/EOT -DB for subjects assigned to placebo during the double -blind treatment 
period). 
• Change from macitentan Baseline to each time point in WHO functional class   
• Change from macitentan Baseline to each time point in NT-proBNP 
• Change from macitentan Baseline to each time point in 6 -minute walk distance 
(6MWD) 
• Change from macitentan Baseline to each time point in Borg dyspnea index.  
6.2 Safety endpoints  
6.2.1 Double -blind treatment  period  
For the double -blind treatment perio d, treatment -emergent is defined as from first intake 
of study treatment until end of double -blind treatment +  30 days, or initiation of 
open- label treatment, whichever occurs first) . 
• Treatment -emergent deaths  
• Treatment -emergent AEs  
• Treatment -emergent AEs leading to premature discontinuation of double-blind study 
treatment  
• Treatment -emergent SAEs  
• Proportion of patients with treatment -emergent ALT and/or AST abnormality ( ≥ 3, 
≥ 5, and ≥  8 × ULN)  
• Proportion of pati ents with treatment- emergent ALT and/or AST abnormality  
(≥ 3 × ULN) associated with  total bilirubin ≥  2 × ULN  (and increased as compared to 
baseline) up to EOT- DB 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 57/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• Proportion of patients with treatment -emergent hemoglobin abnormality (< 100 g/L, 
and < 8 0 g/L)  
• Treatment -emergent marked lab abnormalities  
• Change from Baseline to EOT -DB in vital signs  
• Change from Baseline to EOT -DB in laboratory variables  
• Change from Baseline to EOT -DB in MELD score  
• Change from Baseline to EOT -DB in C hild-Pugh class ification . 
Marked lab oratory abnormalities are defined in Actelion internal guidelines as detailed in  
Appendix 6. 
6.2.2 Macitentan -treatment period safety endpoints  
Macitentan treatment -emergent is defined as from first intake of macitentan up t o EOS  
(i.e., 30 days after discontinuation of macitentan treatment). End of macitentan  treatment 
(EOMT) is defined as EOT -DB or EOT -OL, whichever comes last. Macitentan baseline 
is defined as last assessment prior to first intake of macitentan.  
• Macitentan treatment- emergent  deaths 
• Macitentan treatment -emergent  AEs  
• Macitentan treatment -emergent  AEs leading to premature discontinuation of 
macitentan treatment 
• Macitentan treatment -emergent  SAEs  
• Proportion of patients with macitentan treatment -emergent ALT and/ or AST 
abnormality ( ≥ 3, ≥ 5, and ≥  8 × ULN) up to EOMT 
• Proportion of patients with macitentan treatment -emergent ALT and/or AST 
abnormality ( ≥ 3 ULN) associated with  total bilirubin ≥  2 × ULN  (and increased as 
compared to baseline)  up to EOMT  
• Proportion of patients with macitentan treatment- emergent hemoglobin abnormality 
(< 10 0 g/L, and < 80 g/L) up to EOMT  
• Macitentan treatment -emergent marked lab abnormalities up to EOMT  
• Change from macitentan Baseline to EOMT  in vital signs  
• Change from macitentan Baseline to EOMT  in laboratory variables  
• Change from macitentan Baseline to EOMT  in Child -Pugh classification  
• Change from macitentan Baseline to EOMT  in MELD Score . 
6.3 Pharmacokinetic endpoints  
A PK  substudy will be performed in consenting patients  at any time on o r between  Visit 6  
/ Week 16  and Visit 7  / Week 20  (open -label p eriod). Recruitment into the substudy will 
be stopped only after  a minimum of  20 subjects have provided sufficient plasma samples 
of good quality to allow evaluation of the PK  profile of macite ntan in PoPH. Please see 
Appendix 1 for a detailed description of procedures. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 58/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
7 STUDY ASSESSMENTS  
All study assessments are performed by a qualified study staff member: medical, nursing, 
or specialist technical staff, and are recorded in the e CRF, unless otherwise specified. 
Study assessments performed during unscheduled visits will also be recorded in the eCRF. When applicable, the assessments should be performed in the following order:  
• Blood sampling 
• Physical examination   
• WHO functional cl ass  
• 6-minute walk test 
• Borg dyspnea index 
• Right  heart/hepatic vein  catheterization at rest  
If the principal investigator  delegates any study procedure/assessment for a subject, 
e.g., RHC, blood sampling etc., to an external facility, he/she should inform Actelion to 
whom these tasks are delegated. The set -up and oversight will be agreed upon with 
Actelion. The supervision of any external facilities remains under the responsibility of the principal inve stigator . 
Calibration certificates for the following devices used to perform study assessments must be available prior to the randomization of the first subject:  
• Temperature measurement devices for study medication storage area and freezer , 
• Right  heart /hepatic  catheterization equipment, 
• Scale for measuri ng body weight. 
7.1 Screening/baseline assessments 
Date of informed consent, baseline demographics  (sex, age, race, ethnicity, body weight, 
height) as well as a reason for why a woman i s not considered to be of childbearing 
potential (if applicable) are to be recorded in the eCRF at Visit 1/Screening only after 
informed consent has been signed. 
Complete, clinically relevant medical history (previous and ongoing at randomization) as 
described in S ection 4.6 and liver  disease characteristic s: 
• Date and mode of portal hypertension diagnosis ( liver biopsy, hepatic vein 
catheterization, ultrasound, presence of esophageal varices, ascites, history of TIPS , 
other 
• Cause of portal hypertension: Intrahepatic ( autoimmune hepatitis, alcohol cirrh osis, 
hepatitis B  cirrhosis , hepatitis C  cirrhosis , nonalcoholic steatohepatitis, primary 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 59/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
biliary cirrhosis ); pre -hepatic (portal vein thrombosis/clots, congenital); post -hepatic 
(hepatic vein thrombosis, inferior vena cava thrombosis); other 
• Child -Pugh class and/or MELD Score are also to be assessed and documented in the 
eCRF at Visit 1/Screening . 
PAH disease characteristics such as 6MWT, Borg dyspnea index, WHO functional class , 
as well as vital signs , body mass index , and ongoing medications are to be documented in  
the eCRF at Visit 1/Screening.  
Right heart and hepatic  vein catheterization data are to be collected in the eCRF  at 
Visit 1/Screening.  Hepatic vein catheterization is  not a required procedure for study entry 
but should be collected where possib le. Reason for Screen failure,  if applicable, must also 
be given in the eCRF at Visit 1/Screening.   
At Visit 2/Randomization, WHO functional class, 6MWT, Borg dyspnea index, and 
ongoing medications are to be collected in the eCRF. Any SAEs occurring durin g 
Screening relating to study -mandated procedures are to be documented in the eCRF.  
A physical examination of the subject should be performed at both Visit 1/Screening and 
Visit 2/Randomization . Data are  not collected in the eCRF  though abnormal findings a re 
to be recorded as AEs . Serum laboratory and pregnancy testing should be performed at 
Visit 1/Screening and repeated at Visit 2/Randomization  (urine pregnancy test required in 
addition at Visit 2  prior to randomization [ see Section 4.3]) , whereas blood sampling for 
baseline NT -proBNP sh ould only be performed at Visit  2/Randomization. Laboratory 
data are only collected in the eCRF  for local lab assessments [ see Section 7.3.5 ]. Only 
laboratory data f rom Visit 1/Screening are to be considered for subject eligibility . Vital 
signs are to be assessed and documented in the eCRF at Visit 1/Screening.  
AEs and SAEs occurring during the Screening and Randomization Visit phase are to be documented in the eCRF.  
7.2 Efficacy assessments 
7.2.1 Hemodynamic measurements − Right heart catheterization  
Invasive cardiac hemodynamic variables  are measured  according to the Actelion RHC 
guidelines (see  the PORTICO catheterization handbook) at Baseline and Week 12, or at 
permanent d iscontinuation of double -blind study treatment if prior to Week 12 (at the 
investigator’s discretion) .  
A maximum of 2 RHC are performed during the study duration. Catheterizations should be performed according to the Actelion guidelines and the t hermodilution technique 
should be used to measure cardiac output ( CO).  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 60/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
The following variables  are to be measured and collected in the eCRF: Heart rate (HR), 
PAWP or LVEDP  (if PAWP is not available), mRAP, systolic/diastolic/mean PAP, CO, 
SVO 2. Non-invasive SBP and diastolic blood pressure (DBP) are collected and entered 
into the eCRF . PVR will be calculated locally and entered into the e CRF at 
Visit 1/Screening.  
The following hemodynamic variables  will be calculated by Actelion  for analysis 
purposes [ see Section 11.2 and the PORTICO catheterization handbook for formulae ]: 
PVR, TPR, CI.  
RHC reports , including traces, must be signed by the person performing the procedure, or 
by the principal in vestigator and filed at site in the subject’s file.  
7.2.2 Hemodynamic measurements − Hepatic vein  catheterization  
HVPG, an estimate of portal pressure, is measured  by hepatic vein catheterization  (HVC) 
at Baseline and Week 12, or at permanent discontinuation of double -blind study 
treatment  if prior to Week  12 (at the investigator’s discretion). 
HVPG should be measured at the same time as RHC variables  where possible, but within 
1 week prior to EOT -DB if the procedure cannot be performed on the same day . HVC is 
not required at sites that do not perform the procedure routinely. 
HVPG measurements  will be done after at least 4 hours of fasting, at rest, in the supine 
position, under local anesthesia and mild sedation. A catheter introducer will be placed 
into the right jugular vein (or femoral) by the Seldinger technique. It will be used to advance a balloon- tipped catheter into the main right hepatic vein for repeated 
measurements of wedged (occluded) and free hepatic venous pressures. Intravascular pressures will be measured using highly sensitive pressure transducers, calibrated before each measurement. HVPG will be calculated as the difference between wedged and free hepatic venous pressures. Measurements will be performed at least as duplicates and repeated until, ideally, the 2 consecutive reliable measurements do not differ by more than 1 mmHg. The mean of these two measurements will be considered final. It is up to the investigator, according to his best clinical judgment, to identify the reliable value in case that this requirement is not fulfilled. Only the final value will be recorded in the CRF.  
HVC reports must be signed by the person performing the procedure, or by the principal investigator. Corresponding HVC documents must be filed at site in the subject’ s file.  
7.2.3 WHO functional cl ass 
WHO functional cl ass is evaluated at Screening, Baseline/Randomization, and then every 
Visit until EOT -DB or EOT -OL, whichever comes last  [see Appendix 5 for more details 
on performing the assessment]. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 61/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
7.2.4 6-minute walk test  
The 6MWT [ ATS Statement 2002] is evaluated at Screening, Baseline/Randomization, 
and then every Visit until EOT -DB or EOT -OL, whichever comes last. It is a test which 
measures the distance walked by the subject in six minutes.  
Detailed g uidelines on the correct execution  of this test, the “ Actelion guidelines for 
6MWT” , can be found in the Appendix 3. It is important that for each individual subject 
the 6MWT is conducted under the same conditions throughout the s tudy (e.g., same 
location, same tester, same time of day, with or without nasal  oxygen therapy [and with 
same flow rate as Baseline]) . 
7.2.5 Borg dyspnea index 
The Borg dyspnea index is evaluated after each 6MWT. It rates dyspnea on a scale from 
0 to 10 [s ee Appendix 4 for more details on performing the assessment]. 
7.2.6 Serum NT-proBNP  
A blood sample will be drawn at Baseline/Randomization (Visit 2), EOT -DB, and  
EOT -OL for the analysis of  serum  NT-proBNP.   
Serum NT -proBNP samples will be  shipped to the central laboratory on dry ice as soon 
as possible after blood sample has been drawn or  stored frozen at − 20 °[ −4 °F] ± 2  °C 
[± 3.6 °F]  until the shipment  can occur . A temperature log must be maintained and 
temperature control should occur at l east on a weekly basis. NT -proBNP samples will be 
processed through the central laboratory and the results will be sent electronically to Actelion on an ongoing basis. Further details regarding blood sampling procedures, collection and shipment of biomarke r samples are described in the central laboratory 
manual.    
7.3 Safety assessments 
The definitions, reporting and follow -up of AEs, SAEs [ and pregnancies]  are described in 
Section 10. 
7.3.1 Vital signs  
Vital signs (BP, pu lse rate) will be measured at Screening  (Visit 1), EOT -DB, and 
EOT -OL, and entered  in the eCRF. BP (systolic and diastolic) and pulse rate will be 
measured in a supine or sitting position after the subject has rested for at least 5 minutes. 
The right or left arm may be used. The same position and arm should be used throughout the trial for an individual subject. When applicable, vital signs should be measured before the 6MWT.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 62/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
7.3.2 Weight and height  
Height and weight are measured at Visit 1/Screening  and entered  into the eCRF . Weight 
is measured again at EOT -DB. 
7.3.3 Physical examination 
Physical examination (i.e., inspection, percussion, palpation and auscultation) is to be 
performed during the course of the study. If an abnormality is found it should be specified in the e CRF, describing the signs related to the abnormality (e.g., systolic 
murmur) and not the diagnosis (e.g., mitral valve  insufficiency). Clinically relevant 
findings (other than those related to PoPH ) that are present at study start (i.e. , signing of 
informed consent) must be recorded on the Medical History CRF page. P hysical 
examination findings made after study start, which meet the definition of an AE [Section  10.1.1] must be recorded by the investigator on the AE page of the CRF. 
7.3.4 Child -Pugh classification and/or MELD Score assessment  
Assessment of liver disease severity using the Child -Pugh classification and/or MELD 
Score [ see Appendix 2
 for definitions ] is to be performed at Screeni ng/Visit 1 , EOT -DB, 
and EOT -OL and entered into the e CRF. Serum laboratory analyses used for calculating 
either assessment  must be performed using study lab kits  but local labs may also be used 
in parallel  and data entered into the eCRF . An ultrasound scan of the abdomen should be 
performed for assessing the Child- Pugh class . Data must be complete for Screening 
purposes. 
In case a patient has progressed to Child- Pugh C or MELD Score ≥ 19 at Week 12, 
open- label  medication must not be started. Serum laboratory analyses used for calculating 
either assessment must be performed using study lab kits but local labs may also be used in parallel  and data entered into the eCRF. EOS must be completed after a 30 -day Safety 
follow-up period.  
7.3.5 Laboratory assessments 
7.3.5.1 Type of laboratory 
A central laboratory ( ) will be 
used for all protocol -mandated l aboratory tests, including re -tests due to laboratory 
abnormalities and laboratory tests performed at unscheduled visits. Central laboratory data will be automatically transferred from the central laboratory database to Actelion ’s 
clinical database.   
Eligibility of subjects in Screening may be determined using local laboratory tests as  long 
as the central laboratory kit is used in parallel. Similarly, at Week 12 (EOT -DB), 
laboratory assessments for calculating the MELD Score and/or Child- Pugh classification  

Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 63/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
may be performed using local laboratory testing if a central laboratory kit is used in 
parallel.  
All local laboratory data must be entered into the clinical database via dedicated e CRF  
pages . The investigator/delegate will provide Actelion with the name,  professional 
degree, and curriculum vitae  of the director of the local  laboratory, a copy of the 
laboratory’ s certification, and the normal ranges for each laboratory test that is evaluated 
in the study. These laboratory references must be updated wheneve r necessary.  
Under specific circumstances (e.g., if the patient  lives far  from the site and cannot return 
every month), laboratory samples may be collected at a laboratory close to where the patient  lives  (satellite laboratory) , and sent to the central lab oratory for analysis. In such a 
case, the satellite  laboratory must be provided with the central laboratory sampling kits. 
Shipment of the samples will be organized by the satellite  laboratory. If this process is 
implemented , the satellite  laboratory must be identified prior to enrollme nt of the patient  
in the study. The supervision of the satellite laboratory remains under the responsibility of the principal investigator. 
In exceptional cases (e.g., patient  is hospitalized in a different hospital from the study 
center due to a medical emergency , missing laboratory values) the local laboratory results 
(with the corresponding normal ranges) will be entered into  the clinical database via 
dedicated CRF  pages.  
In case a central laboratory sample is lost or cann ot be analyzed  for a ny reason, the 
investigator will collect an additional sample as soon as possible for repeat analysis, 
unless a local laboratory sample was collected  within the same time -window and these 
test results are available.  
Central laboratory r eports will be sent to the investigator. In case of specific (pre -defined) 
laboratory abnormalities, the central laboratory will alert Actelion and the concerned site. Alert flags that will trigger such notifications are displayed in  Appendix 7. 
All laboratory reports must be signed and dated by the pri ncipal  investigator or delegate 
within 3 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values are considered clinically relevant or not. Clinically relevant laborat ory findings that are 
known at the time of informed consent signature must be recorded on the medical history page of the CRF . Any clinically relevant laboratory abnormalities detected after informed 
consent signature must be reported as an AE or SAE as appropriate [ see Section  10], and 
must be followed until the value returns to within the normal range or is stable , or until 
the change is no longer clinically relevant. Further laboratory analyses must be performed 
as indicated and according to the judgment of the investigator. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 64/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Details about the collection, sampling, storage, shipment procedures, and reporting of 
results and abnormal findings can be found in the laboratory manual. 
7.3.5.2 Laboratory tests 
The total amount of blood collected during the study will not exceed 200 mL: 1. At Visit 1/Screening approximately 15 mL of blood will be collected  
2. At Visit 2/Randomization , EOT -DB and EOT -OL approximately 25 mL of blood will 
be collected  
3. At Visits 3 and  4 approximately 15 mL of blood will be collected 
4. At Visits 6 and 7 approximately 15 mL of blood will be collected 
5. At the PK substudy (optional), approximately 24 mL will be collected. 
Hematology  
Hematology tes ts will be performed at every Visit (1 –8) and include: 
• Hemoglobin, hematocrit 
• Erythrocyte count (reticulocyte count)  
• Leukocyte count with differential counts 
• Platelet count . 
Rules for study treatment interruption in case of hemoglobin abnormalities are pro vided 
in Section 5.1.11. 
Clinical chemistry  
• Aminotransferases (AST/ALT), alkaline phosphatase, total and direct bilirubin 
• GGT  
• Bile acids  
• Creatinine, blood ure a nitr ogen (BUN) 
• Uric acid  
• Lactate dehydrogenase ( LDH ), cholesterol, triglycerides  
• Glucose 
• Sodium, potassium, calcium, chloride 
• Albumin , protein. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 65/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Rules for study treatment interruption in case of liver enzymes abnormalities are provided 
in Section 5.1.11. 
Coagulation tests  
• Prothrombin time and International Normalized Ratio ( PT-INR) . 
Pregnancy test  
A serum  pregnancy test for women of childbearing potential will be performed monthly 
from  Visits 1 to 8  and if pregnancy is suspected during the study. At Visit 2 and at the 
end of the 30- day Safety fo llow up, a urine dipstick pregnancy test is to be performed. 
8 SCHEDULE OF VISITS 
Table 1 provides a summary of all visits and assessments described in the following 
sections.  
To ensure compliance, at each visit the study personnel  must remind women of 
childbearing potential to use the methods of contraception defined for this study. The 
reminders must be documented in the hospital chart. 
It is permitted to re-screen subjects once, if the reason for non- eligibility was transient 
(e.g., abnormal laboratory test, insufficient wash -out period of a forbidden medication, 
etc.), provided that documented authorization has been received from Actelion. Only 
screening assessments that will be older than 28 days at the time of randomization nee d 
to be repeated at the time of re- screening.  
8.1 Screening Period  
8.1.1 Screening (Visit 1)  
All Screening assessments must be performed within 28 days prior to Randomization. 
Historical data for Baseline RHC and HVC may be entered into the e CRF if the 
procedure was  performed within 28 days of Randomization and per the requirements 
described in Sections 7.2.1 and 7.2.2. Screening commences with signature of the ICF 
and ends with subject randomization (up to 28 days after signed informed consent).  It is the responsibility of the investigator to obtain written informed consent from each 
subject participating in this study after adequate face to face explanation of the objectives, methods, and potential hazards of the study. The subjects who agree to participa te in the study must sign the I CF prior to any study -related assessment or 
procedure. Screening and Randomization cannot occur on the same day. 
Visit 1 includes :  
• Subject information leaflet and consent form signature  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 66/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• Obtain subject number from IxRS  
• Recording of demographics, medical history, cause of portal hypertension, date and 
method of portal hypertension diagnosis, date of PoPH diagnosis 
• Physical examination  
• Complete laboratory tests, including  serum  pregnancy test for women of childbearing 
potential 
• Child -Pugh and/or MELD score assessment 
• Recording of previous and concomitant medications 
• Recording of methods of contraception (for females of childbearing potential only)  
and initiation of protocol -complian t contraception if applicable. The reason why a 
female is not considered to be of childbearing potential will also be collected in the 
eCRF  
• Measurement of vital signs, height and body weight 
• WHO functional cl ass 
• 6MWT and Borg dyspnea index 
• RHC and HVC  
• Reco rding of AEs and SAEs .  
The investigator will check all the inclusion/exclusion criteria and decide on the subject’ s 
eligibility for the study . HVC is not required at sites that do not perform the procedure 
routinely. Only laboratory data  from Visit 1/Scre ening are to be considered for subject 
eligibility. Eligibility of subjects may be determined using local laboratory tests as long 
as the central laboratory kit is used in parallel  and the results entered into the eCRF . It 
must be verifiable in the source documents that the subject met each of the inclusion criteria and none of the exclusion criteria. If the subject is not randomized, the reason for screening failure is to be documented in the eCRF.  
8.2 Double-blind t reatment period 
8.2.1 Randomization (Visit 2) 
Visit 2 corresponds to the start of the treatment period (Day 1 of the study) for subjects 
that are eligible after all Screening assessments have been performed. It must take place within 28 days after start of Screening. However, Screening and Randomization cannot take place on the same day.  
Visit 2 includes: 
• Recording of changes in concomitant medications  
• Assessment of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• WHO functional class  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 67/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• 6MWT and Borg dyspnea index  
• Complete laboratory tests, including serum & urine pregnancy test for women of 
childbearing potential [see Section 4.3]  
• Blood sample for serum  NT-proBNP  
• Recording of AEs/SAEs:  
− All AEs occurring after study treatment initiation are to be reported in the eCRF  
− All SAEs occurring after signing of the ICF are to be reported in the eCRF and on 
an SAE form . 
Laboratory values from Visit 2/Randomization are not to be considered for subject eligibility. After compl etion of all Screening and Randomization assessments and 
confirmation of eligibility (i.e., verification of all entry criteria) by the investigator:  
o Randomization via I xRS to obtain Randomization and study treatment bottle 
number 
o Dispensing of 1 bottle of study treatment [see Section 5.1.7.3] 
8.2.2 Week 4 (Visit 3)  
Visit 3 is scheduled 4 weeks (± 4 days) after Randomization .  
Visit 3 includes: 
• Recording of changes in concomitant medications  
• Assessment of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• WHO functional class  
• 6MWT and Borg dyspnea index  
• Complete laboratory tests, including serum pregnancy test for women of childbearing 
potential [see Section 4.3]  
• Recording of AEs and SAEs  
• Study medication return and dispensing of a new bottle . 
8.2.3 Week 8 (Visit 4)  
Visit 4 is scheduled 8 weeks (± 4 days) after Randomization .  
Visit 4 includes: 
• Recording of changes in concomitant medications  
• Assessme nt of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• WHO functional class  
• 6MWT and Borg dyspnea index  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 68/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• Complete laboratory tests, including serum pregnancy test for women of childbearing 
potential [see Section  4.3]  
• Recording of AEs and SAEs  
• Study medication return and dispensing of a new bottle. 
8.2.4 EOT -DB (scheduled Visit 5)  
EOT -DB is scheduled 12 weeks (± 4 days) after Randomization, or earlier in case of 
premature discontinuation of double- blind study treatment.   
EOT -DB includes: 
• Recording of changes in concomitant medications  
• Assessment of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• Measurement of vital signs and body weight  
• WHO functional class  
• 6MWT and Borg dyspnea index  
• RHC and HVC  
• Complete laboratory tests, including serum pregnancy test for women of childbearing potential [see Section 4.3]  
• Child -Pugh and/or MELD score assessment  
• Blood sample for serum  NT-proBNP  
• Recording of AEs and SAEs 
• Study medication return and dispensing of open- label medication . 
Once EOT -DB has been performed, subjects should continue the study in the open -label 
treatment period.  
8.3 Open-label treatment period  
8.3.1 Week 16 (Visit 6)  
Visit 6 is scheduled 16 weeks (± 4 days) after Randomization .  
Visit 6 includes: 
• PK substudy, if applicable [see Appendix 1] 
• Recording of changes in concomitant medications  
• Assessment of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• WHO functional class  
• 6MWT and Borg dyspnea index  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 69/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• Complete laboratory tests, including serum pregnancy test for women of childbearing 
potential [see Section 4.3]  
• Recording of AEs and SAEs  
• Study medication return and dispensing of a new bottle. 
8.3.2 Week 20 (Visit 7)  
Visit 7 is scheduled 20 weeks (± 4 days) after Randomization .  
Visit 7 includes: 
• PK substudy, if applicable [see Appendix 1] 
• Recording of changes in concomitant medications  
• Assessment of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• WHO functional class  
• 6MWT and Borg dyspnea index  
• Complete laboratory t ests, including serum pregnancy test for women of childbearing 
potential [see Section 4.3]  
• Recording of AEs and SAEs  
• Study medication return and dispensing of a new bottle. 
8.3.3 EOT -OL (scheduled Visit 8)  
EOT -OL is scheduled 24  weeks (± 4 days) after Randomization, or earlier in case of 
premature discontinuation of open- label  study treatment.  
EOT -OL includes: 
• Recording of changes in concomitant medications  
• Assessment of methods of contraception (for females of childbearing potential only)  
• Physical examination  
• Measurement of vital signs  
• WHO functional class  
• 6MWT and Borg dyspnea index  
• Complete laboratory tests, including serum pregnancy test for women of childbearing 
potential [see Section 4.3]  
• Child -Pugh and/or MELD score assessment 
• Blood sample for serum NT- proBNP  
• Recording of AEs and SAEs 
• Study medication return . 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 70/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
8.4 EOS 
After permanent study treatment discontinuation (double -blind OR open- label), all 
subjects will e nter a 30 -day Safety follow-up period.  
EOS  is scheduled 24  weeks + 30 to 33 days  after randomi zation . It must  be performed at 
least 30 days after study treatment discontinuation (double -blind OR open- label)  and may 
be performed by telephone. 
EOS  includes: 
• Urine pregnancy test  
• Recording of AEs with onset up to 24 hours after study treatment discontinuation 
• SAEs with onset up to 30 days after study treatment discontinuation. 
9 STUDY COMPLETION AND POST-STUDY TREATMENT/MEDICAL 
CARE 
9.1 Study completion  
For an individual subject the study is  only considered completed once EOT -DB or  
EOT -OL has been performed and the 30-day Safety follow up is complete (EOS).  
The study is considered complete when all subjects have performed the 30- day Safety 
follow up ( EOS ).  
9.2 Premature withdrawal from study 
Subjects may voluntarily withdraw from the study for any reason at any time. Subjects 
are considered withdrawn if they state an intention to withdraw further participation in all components of the study, die or are lost to follow -up for any other reason. The 
investigator may withdraw a subject from the study (without regard to the subject ’s 
consent) if, on balance, they believe that continued participation in the study would be contrary to the best interests of the subject. Withdraw al from the study may also result 
from a decision by Actelion for any reason, including premature termination or suspension of the study [see Section 9.3].  
Subjects are considered as lost to follow -up if all reasonable attempts by the investigator 
to communicate with the individual fail. The site must take preventive measures to avoid a subject being lost to follow -up (e.g., document different ways of contact such as 
telephone number, home address, e mail address,  person to be contacted in case the 
subject cannot be reached). If the subject cannot be reached, the site must make a reasonable effort to contact the subject, document all attempts and enter the loss of follow- up information into the e CRF. The following methods must be used: at least three 
documented telephone calls  on different days  must be placed to the last available 
telephone number and one registered letter must be sent by post to the last available home 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 71/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
address. Additional methods may be acceptable if they are compliant with local 
rules/regulations (e.g., site staff visit to the subject ’s home), respecting the subject ’s right 
to privacy. If the subject is still unreachable after all contact attempts listed above, he/she will be considered to be lost to follow-up.  
If premature withdrawal occurs for any reason, the reason for premature withdrawal from 
the study, along with who made the decision (subject, investigator or Actelion) must be recorded in the e CRF.  
If for whatever reason (except death or los s-to-follow- up) a subject was withdrawn from 
the study, the investigator should make efforts to conduct a last visit/contact to assess the safety and well -being of the subject, collect unused study treatment and discuss follow-up 
medical care. The investig ator must provide follow -up medical care for all subjects who 
are prematurely withdrawn from the study, or must refer them for appropriate ongoing care, as described in Section 9.4. 
9.3 Premature termination or suspension of the study 
Actelion reserves the right to terminate the study at any time globally or locally. Investigators can terminate the participation of their site in the study at any time.  
If a study is suspended or prematurely terminated, Actelion will promptly inform the investigators, the IRBs/IECs and Health Authorities, as appropriate, and provide the reasons for the suspension or termination.  
If the study is suspended or prematurely terminated for any reason, the investigator in 
agreement with Actel ion must promptly inform all enrolled subjects, and ensure their 
appropriate treatment and follow -up, as described in Section 9.4. The investigator may be 
informed of additional procedures to be followed in order to ensure that  adequate 
consideration is given to the protection of the subjects’ interests.  
In addition, if the investigator suspends or terminates a study without prior agreement from Actelion, the investigator must promptly inform Actelion and the IRB/IEC, and provide both with a detailed written explanation of the termination or suspension. 
If the IRB/IEC suspends or terminates its approval/favorable opinion of a study, the 
investigator must promptly notify Actelion and provide a detailed written explanation of the termination or suspension. 
Any suspension or premature termination of the study must be discussed with the  
Steering Committee . 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 72/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
9.4 Medical care of subjects after study completion/ withdrawal from study 
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment(s)/medical care 
is necessary and available according to local regulations.  
After premature study withdrawal, the investigator must remind the subject th at he/she 
must not use any other investigational treatment in the 30 days following study treatment  
discontinuation. Female subjects of childbearing potential need to be reminded of the 
requirement to continue using a reliable method of contraception until 30 days after intake of the last dose of study treatment.  
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
10.1 Adverse events  
10.1.1 Definitions of adverse events  
An AE is any adverse change, i.e., any unfavorable and unintended sign, including an abnormal laboratory  finding, symptom or disease that occurs in a subject during the 
course of the study, whether or not considered by the investigator as related to study treatment.   
A treatment- emergent AE is any AE temporally associated with the use of study 
treatment (fro m study treatment initiation until 30 days after study treatment 
discontinuation) whether or not considered by the investigator as related to study treatment.  
AEs include: 
• Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre- existing episodic disease or medical 
condition. 
• Disease or medical condition detected or diagnosed during the course of the study 
even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at study start that worsen following the start of the study.  
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they 
represent a clinically significant finding that was not present at study start or 
worsened during the course of the st udy. 
• Laboratory test abnormalities if they represent a clinically significant finding, 
symptomatic or not, which was not present at study start or worsened during the 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 73/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
course of the study or led to dose reduction, interruption or permanent discontinuation 
of study treatment.  
Overdose, misuse and abuse of the study treatment should be reported as an AE and, in addition, study treatment errors must be documented in the study treatment  log of the 
CRF.  
10.1.2 Intensity of adverse events  
The intensity of clinical AEs is graded on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the CRF.  
If the intensity of an AE worsens during study treatment administration, only the worst 
intensity should be reported on the AE page. If the AE lessens in intensity, no change in the severity is required.  
The three categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the subject. It does not influence daily activities, and usually does not require intervention. 
 Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort, and usually interferes with daily activities. The subject may not be able to continue in the study, and treatment or intervention is usually needed. 
A mild, moderate, or severe AE may or may not be serious [ see Section 10.3.1] . These 
terms are used to describe the intensity of a specific event. Medical judgment should be 
used on a case- by-case basis.  
Seriousness, rather than severity assessment, determines the regulatory reporting 
obligations. 
10.1.3 Relationship to study treatment  
Each AE must be assessed by the investigator as to whether or not there is a reasonable 
possibility of causal relationship to the study treatment, and reported as either related or 
unrelated. The determination of the likelihood that the study treatment caused the AE will 
be provided by an investigator who is a qualif ied physician.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 74/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
10.1.4 Adverse events associated to study design or protocol mandated procedures  
An AE is defined as related to study design or protocol mandated procedures if it appears 
to have a reasonable possibility of a causal relationship to either the study  design or to 
protocol- mandated procedures. Examples include discontinuation of a subject ’s previous 
treatment during a washout period leading to exacerbation of underlying disease. 
10.1.5 Reporting of adverse events  
All AEs occurr ing after study start (i.e., signing of informed consent) and up to 30 days 
after study treatment discontinuation must be recorded on specific AE pages of the CRF.  
10.1.6 Follow- up of adverse events  
AEs still ongoing more than 30 days after study treatment discontinuation must be 
followed up until they are no longer considered clinically relevant. 
10.2 Serious adverse events 
10.2.1 Definitions of serious adverse events  
10.2.1.1 Serious adverse events  
An SAE is defined by the ICH guidelines as any AE fulfilling at least one of the 
following criteria:  
• Fatal . 
• Life-threatening: refers to an event in which the subject was at risk of death at the 
time of the event. It does not refer to an event that hypothetically might have caused death had it been more severe.  
• Requiring inpatient hospitalization, or prolongation of exis ting hospitalization.  
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medically significant: refers to important medical events that may not immediately 
result in death, be life -threatening, or require hospitalization but may be considered to 
be SAEs when, based upon appropriate medical judgment, they may jeopardize the 
subject, and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions above.  
The following reasons for hospitalization are exempted from being reported:  
• Hospitalization for cosmetic elective surgery, or social and/or convenience reasons. 
• Hospitalization for pre -planned (i.e., planned prior to signing informed consent) 
surgery or standard monitoring of a pre -existing disease or medical condition that did 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 75/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
not worsen, e.g., hospitalization for coronary angiography in a subject with stable 
angina pectoris.  
However, complications that occur during hospitalization are AEs or SAEs (for example if a com plication prolongs hospitalization). 
10.2.1.2 Serious adverse events associated with the study design or protocol mandated procedures  
An SAE is defined as related to study design or protocol mandated procedures if it appears to have a reasonable possibility of a c ausal relationship to either the study design 
or to protocol -mandated procedures. Examples include discontinuation of a subject ’s 
previous treatment during a washout period leading to exacerbation of underlying disease or a complication of an invasive procedure that is specifically required by the protocol. 
10.2.2 Reporting of serious adverse events  
10.2.2.1 During screening period  
All SAEs that occur after study start (i.e., signing of informed consent) must be reported 
(whether considered associated or not associated to study design or study -mandated 
procedures).  
These SAEs must be reported on an SAE form and also in the CRF.  10.2.2.2 During treatment period 
All SAEs, regardless of investigator-attributed causal relationship, must be reported. These SAEs must be reported on an SAE form (except if waived [ see Section 10.2.5] ) 
and also on the AE pages in the e CRF.  
10.2.2.3 During 30-day follow-up period 
All SAEs, regardless of investigator -attributed causal relations hip, which occur up to 
30 da ys after study treatment discontinuation must be reported on AE pages in the eCRF 
and on an SAE form (except if waived [ see Section 10.2.5] ).  
10.2.3 Follow- up of serious adverse events  
SAEs still ongoing at the E OS visit must be fol lowed up until resolution or stabilization, 
or until the event outcome is provided, e.g., death.  10.2.4 After the 30-day follow- up period  
New SAEs occurring after the 30- day follow -up period must be  reported to the Actelion 
drug safety department within 24 hour s of the investigator ’s knowledge of the event, only  
if considered causally related to previous exposure to the study treatment by the 
investigator.   
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 76/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
10.2.5 Reporting procedures  
All SAEs must be reported by the investigator to the Actelion drug safety department 
within 24 hours of the investigator’ s first knowledge of the event.  
All SAEs must be recorded on an SAE form, irrespective of the study treatment received 
by the subject, and whether or not this event is considered by the investigator to be related to stud y treatment.  
The SAE forms must be faxed to the Actelion drug safety department (contact details are provided on the SAE form). The investigator must complete the SAE form in English, 
and must assess the causal relationship of the event to study treatment. 
Follow- up information about a previously reported SAE must also be reported within 
24 hours of receiving it. The Actelion drug safety department may contact the 
investigator to obtain further information.  If the subject is hospitalized in a hospital other than the study site, it is the investigator ’s 
responsibility to contact this hospital to obtain all SAE relevant information and 
documentation. 
The reference safety document to assess expectedness of a suspect serious adverse 
reaction and the need for expedited reporting by the sponsor to Health Authorities, ECs/IRBs and investigators is the reference safety information section of the IB [Macitentan IB ].  
10.3 Pregnancy 
If a woman becomes pregnant while on study treatment, study treatment must be discontinued. The investigator must counsel the subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus.  
10.3.1 Reporting of pregnancy  
Irrespective of the treatment received by the subject, any  pregnancy occurring during the 
study including during the 1 month following study treatment discontinuation must be 
reported within 24 hours of the investigator’s knowledge of the event.  
Pregnancies must be reported on the Actelion Pregnancy form, which is faxed to the 
Actelion drug safety department (see contact details provided on the Ac telion Pregnancy 
form), and on an AE page in the e CRF.  
10.3.2 Follow- up of pregnancy  
Any pregnancy must be followed to its conclusion and its outcome must be reported to the A ctelion drug safety department.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 77/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Any AE associated with the pregnancy occurring during the follow -up period after study 
treatment  discontinuation must be reported on separate AE pages in the CRF. Any SAE 
occurring during the pregnancy must be reported on an SAE form as described in 
Section  10.3.1. 
10.4 Study safety monitoring 
Clinical study safety information (AEs, SAEs, laboratory values, vital signs, and project -
specific labs/examinations as required) is monitored and reviewed on a continuous basis 
by the Actelion Clinical team (in charge of ensuring subjects ’ safety as well as data 
quality) by periodically monitoring clinical studies activities from protocol conception to database closure.  
11 STATISTICAL METHODS 
All statistical analys es will be conducted by Actelion or by designated Contract Research 
Organizations supervised by Actelion. 
A Statistical Analysis Plan (SAP) will provide full details of the analyses, data displays, 
and algorithms to be used for data derivations.  
11.1 Analysis Sets  
11.1.1 Screened Analysis Set  
This analysis set includes all patients who were screened and received a screening 
number . 
11.1.2 Full Analysis Set  
The Full Analysis Set (FAS) includes all randomized patients who received at least one 
dose of study treatment in the double- blind treatment period  and have a baseline value for 
the primary endpoint (PVR). 
11.1.3 Per-Protocol Set  
The Per -Protocol Set (PPS) comprises all patients included in the FAS without major 
protocol deviations that might affect the main analysis of the primary efficacy variable. 
The reasons for excluding patients for the PPS will be fully defined and documented in 
the SAP.  
11.1.4 Safety Set  
The Safety Set includes all patients who received at least one dose of study treatment in 
the double-blind treatment period. 
11.1.5 Other analysis sets  
The Macitentan Treated Set (MTS) consists of all patients who received at least one dose 
of macitentan in the double-blind or open- label treatment period. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 78/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
The PK set comprises all patients from the FAS who did not deviate from  the protocol  in 
a way that might affect the evaluation of the PK  endpoints. 
11.1.6 Usage of the analysis sets 
The primary efficacy analysis will be performed on the FAS  based on treatment as 
randomized. Secondary and exploratory efficacy analyses will also be performed on the 
FAS.  
Safety analyses related to the double-blind treatment period will be performed on the 
Safety Set  based on treatment as received . 
Summaries of efficacy and safety data obtained in all subject s who received macitentan 
(regardless of the treatment peri od) will be performed on the MTS. 
Subject  listings will be based on the Safety Set, unless otherwise specified. Subject  
disposition will be described for the Screened Analysis Set. 
Analysis of PK in the PK substudy will be performed on the PK Set.  
11.2 Variabl es 
11.2.1 Primary efficacy variable 
The primary efficacy variable is the relative change from baseline to Week 12 in PVR.  
PVR [dyn·s·cm -5 ]  i s  c a l c u l a t e d  a s  ( m P A P  −  P A W P )  /  C O  ×  8 0  ( also refer to the 
PORTICO catheterization handbook). The relative change from baseline is equal to the 
ratio of Week 12 to baseline PVR, minus one. The ratio of Week 12 to baseline PVR will 
be the variable used in the analyses.  
11.2.2 Secondary efficacy variables  
Secondary efficacy variables are changes from baseline to Week 12 in: 
• mRAP  [mmHg]  
• mPAP  [mmHg]  
• CI [L/min/m2], calculated as CO / body surface area ( BSA ) where  
BSA [m2]= 0.007184 × weight0.425 [kg]  × height0.725 [cm]  
• TPR [dyn·s·cm-5], calculated as mPAP / CO.  
• SVO 2 [%]  
• WHO functional class  [I–IV] 
• 6MWD [m]  
• NT-proBNP [pmol/L] 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 79/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
11.2.3 Other efficacy variables 
11.2.3.1 Double- blind treatment period 
For all patients, c hanges from baseline to Week 12 in:  
• HVPG [mmHg]  
• Borg dyspnea index (range 6 –20) 
11.2.3.2 Macitentan  treatment period 
For patients who received macitentan  in the double- blind or open- label treatment period, 
changes from macitentan B aseline to each time point  for the following variables: 
• WHO functional class  
• 6MWD 
• NT-proBNP  
• Borg dyspnea index 
Macitentan baseline is defined as last assessment prior to  macitentan initiation, i.e., f or 
patients who received macitentan  already in the double-blind period baseline is the start 
of double -blind macitentan  and for patients who re ceived macitentan  only in the 
open- label  period baseline is Week 12 . 
11.2.4 Safety variable s 
11.2.4.1 Double- blind treatment period 
Treatment -emergent is defined as from first intake of study treatment until to end of 
double- blind treatment + 30 days or start of open- label treatment, whichever occurs first . 
For all patients, s afety variables include:  
• Treatment -emergent AEs  up to EOT- DB 
• Treatment -emergent death s up to EOT- DB 
• Treatment -emergent SAEs  up to EOT- DB 
• AEs leading to prematur e discontinuation of study treatment up to EOT -DB 
• Occurrence of LFT (ALT or AST) abnormalities  up to EOT- DB, classified as:  
o ≥ 3 × ULN;  
o ≥ 3 × ULN and < 5 × ULN;  
o ≥ 5 × ULN and < 8 × ULN;  
o ≥ 8 × ULN.  
• Occurrence of hemoglobin abnormalities up to EOT- DB, classified as:  
o < 80 g/L; 
o ≥ 80 g/L and < 100 g/L . 
• Occurrence of ALT and/or AST abnormality ≥  3 × ULN associated with total 
bilirubin ≥ 2 ×  ULN ( and increased as compared to baseline) up to EOT- DB 
• Treatment -emergent marked laboratory abnormalities up to EOT- DB 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 80/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• Change from baseline to EOT -DB in vital sign s 
• Change from baseline to EOT -DB in laboratory variables  
• Change from baseline to EOT -DB in Child -Pugh classification   
• Change from baseline to EOT -DB in MELD score 
11.2.4.2 Macitentan  treatment period 
For patients who received macitentan  in the double- blind or open- label treatment period 
the same safety variables as in the Section 11.2.4.1 will be considered with macitentan 
treatment emergent instead of treatment emergent, and EOMT instead of EOT-D B. 
11.2.5 Other variables  
Variables associated w ith the PK substudy are described in Appendix 1. 
11.3 Description of statistical analyses 
11.3.1 Overall testing strategy  
The overall type I error is α  = 0.025 (one -sided). The type II error is set to 0.10 and the 
power to 90%.  
11.3.2 Analysis of the p rimary efficacy variable(s)  
11.3.2.1 Hypotheses and statistical model 
The null hypothesis is: The treatment difference (macitentan minus placebo) in mean relative change from 
baseline to Week 12 in PVR is greater than or equal to zero  or, equivalently, the 
geometri c mean ratio ( macitentan  versu s placebo) of the ratios of Week 12 to baseline 
PVR is greater than or equal to one. 
The alternative hypothesis is:  
The treatment difference in mean relative change from baseline in PVR is less than zero  
or, equivalently, the geometric mean ratio is less than one . 
11.3.2.2 Handling of missing data 
If PVR cannot be calculated due to missing PAWP but mPAP and CO are available for the same visit, one the following will be applied:  
1. If PAWP is missing both at baseline and post -baseline, the treatment group medians 
will be imputed (based on the FAS). 
2. If PAWP is missing either at baselin e or post -baseline, the patient ’s available PAWP 
will be imputed.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 81/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
This imputation is based on the clinical assumption that macitentan does not affect 
PAWP.  
Base line: Patients without a baseline PVR measurement will be excluded from the 
analyses.  
Post-baseline:  In patients with a post -baseline PVR measurement obtained before 
Week  12, the post- baseline PVR measurement will be carried forward.  For patients where 
no post- baseline PVR measurement is available, data will be imputed. Imputation rules 
will be specified in the SAP.  
11.3.2.3 Main analysis 
The primary analysis will be performed on the FAS.  
PVR will be summarized by time point and treatment group using descriptive statistics as 
well as geometric means and Coefficients of Variation (CVs). The ratio of Week 12 to baseline PVR will be summarized similarly.  
The ratio of Week 12 to baseline PVR will be log -transformed (base e) and analyzed 
using an Analysis of Covariance (ANCOVA) with factors for treatment group (macitentan v ersus placebo), background PAH -specific therapy at baseline, region and a 
covariate for baseline log PVR. The treatment group differ ence (on log scale) and its 
95% confidence in terval  will be estimated  based on the model. The geometric mean ratio 
(macitentan v ersus placebo) and its 95% confidence in terval  will be obtained by 
exponentiation. The null hypothesis will be rejected if the entire 95% confidence i nterval  
is below one. 
The log transformation for PVR is justified by the fact that ratios versus baseline follow a 
normal distribution more closely after a log transformation. In addition, mean absolute 
changes from baseline on log scale can be translated into (geometric) mean ratios by exponentiation.  
The treatment effect will be expressed as ( Geometric Mean Ratio [ GMR ]-1) × 100%, 
where a negative value indicates a reduction of P VR in the macitentan group as compared 
to the placebo group.  
11.3.2.4 Supportive/sensitivity analyses  
A sensitivity analysis will be  performed on the FAS where, for  patients with a 
post- baseline PVR measurement obtained before Week 12,  a model -based imputation 
will be used for the log-transformed PVR: 
• log PVR [at Week 12] = log PVR [ at week t<12] + (12 -t) × slope  where  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 82/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
• slope  is the expected change from baseline in log PVR based on the main analysis 
model , restricted to patients who had their post- baseline PVR measurement  at 
Week  12. 
Another sensitivity analysis will be performed on the PP set that will (at least) be 
restricted to completers, i.e. , patients with a Week 12 PVR measurement taken at 
Week  12. 
Additional sensitivity analyses may be specified in the SAP.  
11.3.2.5 Subgroup analyses 
A subgroup analysis for the primary endpoint will be performed for patients with versus 
without PAH -speci fic therapy at baseline using the ANCOVA model specified in  
Section 11.3.2.3, but without the factor for PAH- specific therapy.  
Another subgroup analysis will be performed by region using the ANCOVA model without the factor for region.  
Additional subgroup analyses will be specified in the SAP. Interactions between 
treatment and subgroups will be explored. 11.3.3 Analysis of the secondary efficacy variable(s) 
Secondary efficacy analyses will be performed on the FAS  at α = 0.025 (one -sided) using 
95% confidence in tervals . No correction for multiple testing will be applied for these 
analyses.  
Changes from baseline to Week 12 in pressure -volume variables (mRAP, mPAP, CI, 
TPR) and SVO
2 will be summarized and analyzed as des cribed in Section 11.3.2.3, but 
without the log- transformation . 
WHO functional class  will be summarized by time point and treatment group  using 
frequency tables. Changes from baseline in WHO functional class  will be dichotomize d 
as worsening (i.e., change > 0) versus no change or improvement (i.e., change ≤ 0). 
Worsening will be analyzed using a logistic regression model with covariates for 
treatment group, background PAH- specific therapy at baseline and region.  
6MWD will be summarized by time point and treatment grou p using descriptive 
statistics. Change from baseline to each time point  will be summarized similarly. Change 
from baseline in 6MWD will be analyzed using a repeated measurements model with 
factors for treatment group, time point,  treatment by time interaction, background PAH -
specific therapy at baseline and region , and covariates for baseline 6MWD  and WHO 
functional class . An unstructured covariance matrix will be used to account for the 
correlation between repeated measurements from the same subject . NT-proBNP will be 
summarized by time point and treatment group  using descriptive statistics as well as 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 83/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
geometric means and CVs.  The ratio of Week 12 to baseline NT -proBNP will be 
summarized similarly. The ratio versus  baseline in NT -proBNP will be log -transform ed 
and analyzed using an ANCOVA with covariates for treatment group, background PAH -
specific therapy at baseline, region and baseline log NT -proBNP.  
11.3.4 Analysis of the other efficacy variables 
Changes from baseline to Week 12 in HPVG and Borg dyspnea index ( related to the 
double- blind treatment period) will be summarized by treatment group in the FAS using 
descriptive statistics.  
Changes from macitentan baseline to each time point  in WHO functional class , 6MWD, 
NT-proBNP and Borg dyspnea index (related to the  macitentan  treatment period) will be 
summarized for the MTS using descriptive statistics.  
11.3.5 Analysis of the safety variables 
The safety analyses described below will be performed on the Safety Set  for data from 
the double -blind treatment period. For these analyses the (double -blind) 
treatment -emergent period is defined from start of double -blind treatment up to the start 
of open- label treatment or 30 days after double -blind treatment discontinuation, 
whichever occurs first.  
The safety analyses will also be p erformed on the MTS  for data from the macitentan  
treatment period. For these analyses , macitentan treatment -emergent is defined as from 
first intake of macitentan up to EOS  (i.e., 30 days after discontinuation of macitentan 
treatment). EOMT is defined as E OT-DB or EOT -OL, whichever comes last. Macitentan 
baseline is defined as last assessment prior to intake macitentan.  
All safety data will be listed, with flags for quantitative abnormalities.  
11.3.5.1 Adverse events  
A treatment -emergent AE is any AE temporally asso ciated with the use of a study 
treatment . The number and percentage of patients experiencing treatment emergent AEs 
and SAEs at least once will be tabulated by  treatment group and by: 
• MedDRA System organ class (SOC) and individual preferred term within each SOC, 
in descending order of incidence. 
• Frequency of patients with events coded with the same preferred term, in descending 
order of incidence.  
Furthermore, treatment -emergent AEs and SAEs will be tabulated as described above by 
severity and relationship to study treatment.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 84/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
AEs leading to premature discontinuation of study treatment and death will also be 
summarized as described above.  
Listings will be provided for all reported AEs, including SAEs. In addition, separate listings will be provided for SAEs, for AEs leading to premature discontinuation of study treatment , and for AEs leading to death. 
11.3.5.2 Laboratory variables 
Descriptive summary statistics by visit and treatment group will be provided for observed values and absolute changes from baseline, in both hematology and blood chemistry laboratory tests. In order to minimize missing data and to allow for unscheduled visits, all recorded assessments up to EOT -DB plus 30 days will be assigned to the most 
appropriate visit time point according to the best fitting time -window for that assessment. 
Actelion internal guidelines will be used for the definitions of marked abnormalities and for the standardization of numeric values obtained from different laboratories and/or using different normal ranges. Standard numeric laboratory variables are transformed to standard units. All laboratory data transferred are taken into account regardless of whether they correspond to scheduled (per protocol) or unscheduled assessments.  
Marked laboratory abnormalities will be su mmarized for each laboratory parameter by 
treatment group providing their incidence and frequency. Absolute values and changes 
from baseline of laboratory parameter values during the course of the study will be summarized using the usual location and scale summary statistics by treatment group.  
Laboratory variables  are the following: 
• Hematology: hemoglobin, hematocrit, erythrocyte count, leukocyte count with differential counts, platelet count, prothrombin time and coagulation tests ( PT-INR). 
• Blood chemistry: AST, ALT, alkaline phosphatase, total and direct bilirubin, LDH, creatinine, uric acid, glucose, cholesterol, triglycerides, Sodium, potassium, chloride, calcium, protein, albumin, GGT, bile acids, and BUN. 
The number and percentage of patients with LFT abnormalities (classified as in  
Section 11.2.4) will be tabulated by treatment group.  
The number and percentage of patients with hemoglobin abnormalities (classified as in Section 11.2.4) will be tabulated  by treatment group . 
11.3.5.3 Vital signs and body weight  
Blood pressure (i.e., DBP and SBP), HR , and body weight will be summarized for each 
study visit where recorded  using the usual location and scale summary statistics by 
treatment group for both absolute values and changes from baseline. Patients for whom 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 85/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
no post -baseline value is available are excluded from the analysis of the changes from 
baseline in the Safety Set.  
Changes from baseline in Child -Pugh score and MELD score  will be summarized 
similarly as vital signs.  
11.3.6 Analysis of other variables 
See Section 4.3.1 of Appendix 1 for analysis of PK  variables.  
11.4 Interim analyses 
No interim analysis is planned for this trial.  
11.5 Sample size  
11.5.1 Sample size justification  
An integrated an alysis o f two bosentan studies, BENEFIT  (AC-052-366) and EARLY  
(AC-052-364), and the hemodynamic substudy of SERAPHIN  (AC-055-302) with 
macitentan suggested that the treatment group difference  on PVR is expected to be 
around −0.31 on log scale (95% confidence intervals : −0.38, −0.23) and that the within 
group standard deviation (SD) is around 0.41 on log scale (90% confidence 
intervals : 0.39, 0.43). Under these assumptions, 76 evaluable patients will be needed for 
90% power (3 8 patients per group). Accounting for 10% non- evaluable patients, 
approximately 84 patients will need to be randomized. 
11.5.2 Sample size sensitivity  
Table 2 gives more details about the integrated analysis of PVR. It also shows the ‘ best’ 
and ‘ worst ’ case sample sizes based on the 95% confidence in terval  around the treatment 
effect for each study as well as for the integrated analysis. It appears that the proposed 
sample size of 84 patients is robust to some deviations from the assumptions given above.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 86/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Table 2 Treatment effects (differences on log -scale as well as % reduction versus  
placebo), variability in integrated analysis of three studies (AC -052-366, 
AC-052-364 and AC-055-302) and associated sample size for 90% power in 
the PORTICO  study.  
Study  Protocol  Treatment  
Effect 95% CI  
of Effect  SD 90% CI  
of SD  Sample  
Size*  Best 
Case  Worst  
Case  
EARLY  AC-052-364 −0.26 −23% −0.41 −0.11 0.50 0.45 0.54 158 64 924 
BENEFIT AC-052-366 −0.25 −22% −0.35 −0.15 0.32 0.29 0.35 70 36 204 
SERAPHIN AC-055-302 −0.45 −36% −0.58 −0.32 0.38 0.35 0.43 32 20 64 
Overall   −0.31 −27% −0.39 −0.23 0.41 0.39 0.44 76 48 132 
Corrected fo r 
Baseline PVR   −0.31 −26% −0.38 −0.23 0.41 0.39 0.43 76 48 132 
*For 90% power and a two -sided alpha of 5%  
Best case: based on l ower limit of 95% CI for effect  
Worst case: based on upper limit of 95% CI for effect  
CI = confidence interval; PVR = pulmonary vascular resistance; SD = standard deviation.  
12 DATA HANDLING 
12.1 Data collection 
The investigator/delegate is responsible to ensure the accuracy, completeness, and timeliness of the data reported. All source documents should be completed in a neat, legible man ner to ensure accurate interpretation of the data. Data reported in the e CRF 
derived from source documents must be consistent with the source documents. 
CRF data will be captured via electronic data capture (EDC using the Rave system 
provided by Medidata S olutions, Inc., a web- based tool). The investigator and site staff 
will be trained to enter and edit the data via a secure network, with secure access features (username, password and identification – an electronic password system). A complete 
electronic audit trail will be maintained. The investigator/delegate will approve the data (i.e., confirm the accuracy of the data recorded) using an electronic signature (ref. to 21 CFR  Part 11).  
Subject Screening and Enrollment data will be completed for all subjects (i.e., eligible and non- eligible) through the IxRS system and e CRF.  
For each subject enrolled, regardless of study treatment initiation, a CRF must be 
completed and signed by the investigator/delegate. This also applies to those subjects who fail to complete the study. If a subject withdraws from the study, the reason must be noted on the CRF.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 87/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
12.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On CRFs or 
other documents submitted to Actelion, subjects must be identified only by number, and never by name or initials , hospital numbers or any other identifier. The 
investigator/delegate must keep a subject identification code list, at the site, showing the randomization number, the subject ’s name, date of birth and address or any other locally 
accepted identifiers. Documents identifying the subjects (e.g., signed ICFs) must not be 
sent to Actelion, and must be kept in strict confidence by the investigator/delegate. 
12.3 Database management and quality control 
Electronic CRFs will be used for all subjects. The investigator will have access to the site CRF data until the database is locked . Thereafter, they will have read -only access.  The 
CRF must be kept current to reflect subject status at any time  point during the course of 
the study.  
While entering the data, the investigator/delegate will be instantly alerted to data queries by validated programmed checks. Additional data review will be performed by Actelion on an ongoing basis to look for unexpected patterns in data and study monitoring. If 
discrepant data are detected, a query specifying the problem and requesting clarification 
will be issued and visible to the investigator/delegate via the CRF. All electronic queries visible in the system either req uire a data correction (when applicable) and /or a response 
from the investigator/delegate to clarify the queried data directly in the CRF, or simply a data correction in the CRF. The investigator/delegate must, on request, supply Actelion with any required  background data from the study documentation or clinical records. This 
is particularly important when errors in data transcription are suspected. In the case of Health Authority queries, it is also necessary to have access to the complete study records, provided that subject confidentiality is protected. 
This process will continue until database closure. Laboratory samples will be processed through a central laboratory and the results will be 
sent electronically to Actelion. PK  samples will be processed th rough a bioanalytical  
laboratory and the results will be sent electronically to Actelion.  
After the database has been declared complete and accurate, the database will be closed. 
Any changes to the database after that time may only be made as described in  the 
appropriate SOP. After database closure, the investigator will receive the CRF of the subjects of her/his site (including all data changes made) on electronic media or as a 
paper copy.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 88/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
13 PROCEDURES AND GOOD CLINICAL PRACTICE 
13.1 Ethics and Good Clinical Practice 
Actelion and the investigators will ensure that the study is conducted in full compliance 
with ICH -GCP Guidelines, the principles of the “Declaration of Helsinki ” and with the 
laws and regulations of the country in which the research is conducted.  
13.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document provided to the subject (such as Subject Information Leaflet used to obtain informed consent) to an IRB or IEC. Approval from the c ommittee must be obtained before starting the study, and 
must be documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approval.  
Modifications made to the protocol after receipt of the approval must also be submitted as 
amendments by the investigator to the IRB/IEC in accordance with local procedures and regulations [ see Section 13.6]. 
A list of members participating in the IRB/IEC meetings must be provided, inc luding the 
names, qualifications and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation. If a study staff member was present during a meeting, it must be clear that this person did not vote. 
13.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to ICH -GCP guidelines and local regulations from each individual participating in this 
study and/or legal representative. The investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to withdraw from it at any time for any reason.  
The ICF will be provi ded in the country local language(s).  
Site staff authorized to participate to the consent process and/or to obtain consent from the subject and/or legal representative will be listed on Actelion Delegation of Authority form. A study physician must always be involved in the consent process.  
The subject and/or legal representative must sign, personally date and time (if 
appropriate) the ICF before any study- related procedures (i.e., any procedures required by 
the protocol) begin. The ICF must also be signed,  personally dated and timed (if 
appropriate) by the authorized site staff listed on Actelion Delegation of Authority form. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 89/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
A copy of the signed and dated ICF is given to the subject and/or legal representative; the 
original is filed in the site documentation.  
The informed consent process must be fully documented in the subject ’s medical records, 
including study reference, subject number, date/time (if applicable) when the subject was 
first introduced to Actelion clinical study, date/time (if applicable) of  consent, who 
participated in the consent discussion, who consented the subject and any additional person present during the consent process (e.g., subject family member), copy of the signed ICF given to the subject / legal representative.  
In the case that  the site would like to recruit a subject who would be considered as 
vulnerable (e.g., subject cannot read or write , does not speak or understand the ICF 
language), additional measures must be implemented in order to ensure subject rights are respected and  the consent obtained is legally valid. Actelion, the regulatory authorities (if 
applicable) and the IRB/IEC must be informed prior to the recruitment. The consent process (e.g., involvement of an impartial witness) must be fully described, submitted to, and approved by the IRB/IEC, according to procedures and before subjects are recruited .  
13.4 Compensation to subjects and investigators 
Actelion provides insurance in order to indemnify (with both legal and financial coverage) the investigator/site against clai ms arising from the study, except for claims 
that arise from malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations. 
13.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the approved version of the protocol and must not implement any deviation/change from the protocol, except when the change involves only logistical or administrative aspects (e.g., change in telephone number), or in cas e it would be necessary to eliminate an immediate hazard to the 
subject.  
If a protocol deviation occurs, the investigator/delegate will inform Actelion or its 
representative, in a timely manner. The investigator/delegate must document and explain any deviation from the approved protocol. IRB/IEC and regulatory authorities must be informed, according to their requirements, but no later than 15 calendar days after the event.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 90/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
13.6 Protocol amendments 
Any change to the protocol can only be made through a written protocol amendment. A 
protocol amendment must be submitted to IRB/IEC, and regulatory authorities, according to their requirements.  
13.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the reconstruction and evaluation of the study. A number of attributes are considered of 
universal importance to source data and the records that hold those data. These include that the data and records are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, consistent, enduring and available when needed. 
These records are to be classified into two different categories of documents: 
investigator ’s file, and subject clinical source documents.  
These records must be kept by the investigator for as long as is necessary to comply with Actelion ’s requirements (e.g., as specified in the clinical study agreement), and national 
and/or international regulations, whichever would be the longest period. If the investigator cannot guarantee this archiving requirement at the investigational site for any or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Actelion to store these documents outside the site, so that they ca n be retrieved in case of a regulatory inspection. No study document should 
be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion must be notified in advance.  
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as per 21 CFR Part 11 or equivalent standard) and if the monitor has been provided personal and restricted 
access to study subjects only, to verify consistency between electronic source data and the CRF during monitoring visits. 
If the site is using an electronic/computerized system to store subject medical records but 
it could not be confirmed that the system is validated or if the monitor could not be 
provided access to the system, the site is requested to print the complete set of source data needed for verification by the monitor. The print -outs must be numbered, stapl ed 
together with a coversheet, signed and dated by the investigator/delegate to confirm that these certified copies are exact copies having the same information as the original subject ’s data. The printouts will be considered as the official clinical study  records.  
In order to verify that the process the site uses to prepare certified copies is reliable, the monitor must be able to observe this process and confirm that the comparison of the 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 91/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
source documents and the certified copy did not reveal inconsistencies. The monitor does 
not need to verify this process for all data of all subjects but at least for some of them (e.g., first subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per A ctelion ’s instructions. If it were not possible 
for the monitor to observe this process, it would not be possible to rely on the site ’s 
certified copies and therefore the site cannot be selected for the clinical study. The printouts should be filed either with the subject medical records or with the subject’ s 
CRF.  
13.8 Monitoring 
Prior to study start, a site initiation visit (SIV) will be performed after the required essential study documents are approved by Actelion. The study treatment will be shipped to the site upon approval of the required essential documents.  
The principal investigator  must ensure that all site personnel involved in the study will be 
present during the SIV  and will dedicate enough time to it. Site Information Technology 
support should also be available during the initiation visit.  
The SIV must be completed before the site can start the screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow -up letter 
will be provided to the principal inves tigator  and filed in the I SF. 
During the study, the monitor will contact and visit the investigational site regularly, and on request must be permitted to have access to trial facilities and all source documents needed to verify adherence to the protocol and the completeness, consistency and accuracy of the data being entered in the CRFs and other protocol -related documents. 
Actelion monitoring standards require full verification that informed consent has been provided, and verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety and tolerability endpoints. 
Additional checks of the consistency of the source data with the CRFs will be performed 
according to the study -specific monitoring plan. The frequency of the monitoring visits 
will be based on subject recruitment rate and critical data collection times.  
The principal in vestigator must ensure that the CRF is completed after a subject ’s visit to 
the site, and that all requested subje ct files (e.g., ICFs, medical notes/charts, other 
documentation verifying the activities conducted for the study) are available for review by the monitor. The required site personnel must be available during monitoring visits and allow adequate time to meet with the monitor to discuss study related issues.  
The investigator agrees to cooperate with the monitor(s) to ensure that any issues 
detected in the course of these monitoring visits are resolved. If the subject is hospitalized 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 92/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
or dies in a hospital other than the study site, the investigator is responsible for contacting 
that hospital in order to document the SAE, in accordance with local regulations. 
A close- out visit will be performed for any initiated site and when there are no more 
active subjects and after all study data have been accepted by medical review and all 
follow- up issues have been resolved. In case a site does not enroll any subjects, the 
close- out visit may be performed prior to study database closure at the discretion of 
Actelion.  
13.9 Investigator site file 
Each site will be provided with an ISF prior to the initiation visit. It will contain all the essential documents that are required to always be up- to-date and filed at site as per ICH 
GCP section 8. 
The ISF will include a table of conten t listing the essential documents. All study related 
documentation must be maintained in the ISF. In some cases, exceptions can be discussed with the monitor regarding the filing of the 
study documents outside the ISF. It should be clearly documented where  each document 
is filed. This note to file should be present in the specific tab of the document in the ISF. 
The ISF must be stored in a secure and access -restricted  area during and after the study. It 
must be kept by the site for as long as needed to comply with any applicable rules and 
regulations, ICH GCP as well as instructions from Actelion. If the site needs to transfer the ISF to another location and/or if site facility can no longer store the ISF, the principal investigator must inform Actelion imme diately.  
If the principal investigator changes , or if the site relocate s, the monitor must be notified 
as soon as possible.  
13.10  Audit  
Actelion ’s Global Quality Management representative s may audit the investigator site 
(during the study or after its completion). The purpose of this visit will be to determine the investigator ’s adherence to ICH -GCP, the protocol, and applicable regulations ; 
adherence to  Actelion ’s requirements (e.g., SOPs)  will also be verified. Prior to initiating 
this audit, the investigator  will be contacted by Actelion to arrange a time for the audit.  
The investigator and staff must cooperate with the auditor(s) and allow access to all study documentation (e.g., subject records) and facilities. 
13.11  Inspections 
Health Authorities and/or IRB/IEC  may also wish to conduct an inspection of Actelion’ s 
clinical study (during the study or after its completion).  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 93/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Should an inspection be requested by a Health Authority and/or IRB/IEC, the investigator 
must inform Actelion immediately, (usually via the CRA ), that such a request has been 
made.  
The investigator and staff must cooperate with inspector(s) and allow access to all study documentation (e.g., subject records) and study facilities. 
13.12  Reporting of study results and publication  
Study results will be documented in a clinical study report that will be signed by Actelion representatives and the coordinating inve stigator (or principal inv estigator for 
single -center studies).  
The coordinating investigator and the Steering Committee, if any, will have the 
opportunity to review the analysis of the data and to discuss the interpretation of the study results with Actelion prior to publication. 
Actelion will post results from its clinical studies on Actelion ’s Clinical Trial Register, 
and on external/national re gistries, as required by law.  
Actelion ’s Policy on Disclosure of Clinical Research Information can be found at:  
http://www.actelion.com/documents/corporate/policies -charters/policy -scientific -
publications.pdf In accordance with the Good Publication Practi ces and ethical practice, the results of the 
study will be submitted for publication in a peer -reviewed journal. Study results can be 
submitted for presentation at a congress before publication in a peer -reviewed journal. 
Authorship will be determined in accordance with the International Committee of Journal 
Editors (ICMJE) criteria , and be based on: 
• substantial contributions to: the conception or design of the study, or the acquisition, analysis or interpretation of data; and  
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.  
The list of authors of any publication of study results may include representatives of Actelion, and will be determined by mutual agreement.  
Any study- related publication written independently by investi gators must be submitted 
to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 94/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
deletions for the sole purpose of protecting its confidential information and/or patent 
rights. Neither the institution nor the investigator should permit publication during such a review period. 
Actelion ’s Policy on Scientific Publications can be found at: 
http://www.actelion.com/documents/corporate/policies -charters/policy -scientific -
publications.pdf 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 95/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
14 REFERENCES 
[Al-Naamani 2013] Al -Naamani N, Roberts K. Portopulmonary hypertension. Clin Chest 
Med 2013;34:719-737. 
[ATS Statement 2002] Guidelines for the Six -Minute Walk Test. Am J Respir Crit Care 
Med 2002;166:111-7. 
[Benigni 1995] Benigni A. Defining the role of endothelins in renal pathophysiology on 
the basis of  selective and unselective endothelin receptor antagonist studies. Curr 
Opin Nephrol Hypertens 1995;4:349-53.  
[Benza 2010] Benza  RL, Miller DP, Gom berg-Maitland M, Frantz RP, Foreman AJ, 
Coffey CS, et al . Predicting survival in pulmonary arterial hypertension: insights 
from the Registry to Evaluate Early and Long -Term Pulmonary Arterial 
Hypertension Disease Management (REVEAL).  Circulation  2010;122:164-72.  
[Cartin -Ceba 2011] Cartin- Ceba R, Swanson K, Iyer V, Wiesner RH, Krowka MJ. Safety 
and efficacy of ambrisentan for the treatment of portopulmonary hypertension. 
Chest  2011 Jan;139:109-14.  
[Cartin -Ceba 2014] Cartin- Ceba R, Krowka M.J. Portopulmonary hypertension. Clin 
Liver Dis 2014;18:421-438. 
[Chua 1992] Chua B, Krebs CT, Chua CC, et al. Endothelin stimulates protein synthesis 
in smooth muscle cells. Am J Physiol 1992;262:E412-6. 
[Clarke 1989] Clarke J, Benjamin N, Larkin W, et al. Endothelin is a  potent long lasting 
vasoconstrictor in men. Am J Physiol 1989;257:H2033-5. 
[Colle 2003] Colle  IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen- Solal A, et al . 
Diagnosis of portopulmonary hypertension in candidates for  liver transplantation: 
a prospect ive study. Hepatology  2003;37:401-9. 
[Condliffe 2014] Condliffe R, Elliot CA, Hurdman J, Sabroe I, Billings C, Kiely DG, 
Hamilton N. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis 2014;8:71-77.  
[Davie 2002] Davie N, Haleen SJ, Upton PD, et al. ET
A and ET B receptors modulate the 
proliferation  of human pulmonary artery smooth muscle cells. Am J Respir Crit 
Care Med 2002;165:398-405. 
[de Nucci 1988] de Nucci G, Thomas R, D ’Orleans -Juste P, et al. Pressor effects of 
circulating endothelin  are limited by its removal in the pulmonary circulating 
endothelin are limited by its  removal in the pulmonary circulation and by the 
release of prostacyclin -derived relaxing  factor. Proc Natl Acad Sci U S  A 1988; 
85:9797-800.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 96/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
[Galiè 2004] Gali è N, Manes A, Branzi A. The endothelin system in pulmonary arterial 
hypertension. Cardiovasc Res 2004;61:227-37.  
[Ghofrani 2013] Ghofrani  HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, 
et al. Riociguat for  the treatment of pulmonary arterial hypertension. N Engl J 
Med 2013;369:330-40.  
[Giaid 1993]. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin- 1 in 
the lungs of  patients with pulmonary hypertension. N Engl J Med. 1993;328: 
1732–9.  
[Golbin 2007] Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest 
Med 2007;28:203-218. 
[Gough 2009] Gough MS, White RJ. Sildenafil  therapy is associated with improved 
hemodynamics in liver transplantation candidates with pulmonary arterial 
hypertension. Liver Tra nspl 2009 Jan;15:30-6.  
[Halank 2006] Halank M, Ewert R, Seyfarth H -J, Höffken G. Portopulmonary 
hypertension. J Gastroenterol 2006;41:1133. 
[Halank 2011] Halank M, Knudsen L, Seyfarth H -J, Ewert R, Wiedemann B, Kolditz M, 
et al . Ambrisentan improves exer cise capacity and symptoms in patients with 
portopulmonary hypertension. Z Gastroenterol 2011;49:1258-1262. 
[Hemnes 2009] Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary 
hypertension can facilitate liver transplantation. Liver Transpl 2009 Jan;15:15-9. 
[Hirata 1993] Hirata Y, Emori T, Eguchi S. Endothelin receptor subtype B mediates 
synthesis of nitric  oxide by cultured bovine endothelial cells. J Clin Invest 1993; 
91:1367-73.  
[Hoeper 2005] Hoeper  MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et 
al. Bosentan therapy for portopulmonary hypertension. Eur Respir J  2005;25: 
502-508.  
[Hoeper 2007] Hoeper  MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz 
MW, et al . Experience with inhaled iloprost and bosentan in portopulm onary 
hypertension. Eur Respir J.  2007;30:1096-102. 
[Hollatz 2012] Hollatz  TJ, M usat A, Westphal S, Decker C, D ’Alessandro AM, Keevil J, 
et al . Treatment with sildenafil and treprostinil allows successful liver 
transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl 2012 Jun;18:686-95.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 97/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
[Humbert 2006] Humbert  M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et 
al. Pulmonary arterial hypertension in France: res ults from a national registry. Am 
J Respir Crit Care  Med  2006;173:1023-30. 
[Krowka 2006] Krowka  MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. 
Portopulmonary hypertension: Results from a 10- year screening algorithm. 
Hepatology  2006. 44:1502-10. 
[Krowka 2012] Krowka  MJ, Miller DP,  Barst RJ,  Taichman D,  Dweik RA,  Badesch 
DB, McGoon MD. Portopulmonary hypertension: A report from the US -based 
REVEAL Registry. CHEST 2012;141:906-915. 
[Le Pavec 2008] Le Pavec J, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, et al . 
Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit 
Care Med  2008;178:637-643. 
[Macitentan IB] Investigator ’s Brochure. Macitentan ACT -064992. Endothelin receptor 
antagonist, Version 12. Actelion Pharmaceuticals Ltd, November 2014. 
[Massaki 1998] Massaki T. The discovery of endothelins. Cardiovasc Res 1998;39:  
530-533.  
[Pulido 2013] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani A. 
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N 
Engl J Med 2013;369:809-18.  
[Ramsay 1997] R amsay  MA, Simpson BR, Nguyen AT, Ramsay  KJ, East C, Klintmalm 
GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl 
Surg 1997;3:494-500. 
[Reichenberger 2006] Reichenberger  F, Voswinckel R, Steveling E, Enke B, Kreckel A, 
Olschewsk i H, et al. Sildenafil treatment for portopulmonary hypertension. Eur 
Respir J  2006;28:563-567.  
[Robalino 1991] Robalino BD, Moodie DS. Association between primary pulmonary 
hypertension and portal hypertension: analysis of its pathophysiology and clinica l, 
laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-8. 
[Rodriguez- Roisin 2004] Rodríguez- Roisin R1, Krowka MJ,  Hervé P,  Fallon MB;  ERS 
Task Force Pulmonary -Hepatic Vascular Disorders (PHD) Scientific Committee. 
Pulmonary- Hepatic vas cular Disorders (PHD). Eur Respir J 2004;24:861-880. 
[Safdar 2012] Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: An 
update. Liver Transpl 2012;18:881-891. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 98/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
[Sakai 2009] Sakai  T, Planinsic RM,  Mathier MA,  de Vera ME,  Venkataramanan R. 
Initia l experience using continuous intravenous  treprostinil to manage pulmonary 
arterial hypertension in patients with end -stage liver disease. Transpl Int  2009;22: 
554-561.  
[Savale 2013] Savale  L, Magnier R, L e Pavec J, Jaïs X, Montani D, O ’Callaghan DS, et 
al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary 
hypertension. Eur Respir J 2013;41:96-103. 
[Simmoneau 2013] Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, 
Ghofrani A. Updated Clinical Classification of Pulmonary Hyperte nsion. J Am 
Coll Cardiol 2013;62:D34-41. 
[Stewart 1991] Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin -1 in 
pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 
114:464-9. 
[Sugawara 1996] Sugawara F, Ninomiya H, Okamoto Y, et al. Endothelin-1-
inducedmitogenic responses  of Chinese hamster ovary expressing human 
endothelin A: the role of a wortmanninsensitive  signalling pathway. Molec 
Pharmacol 1996; 49:447-57.  
[Wright 2009] Wright G, Porcari JP, Foster CC , et al. Placebo effects on exercise 
performance. Gundersen Lutheren Medical Journal 2009; Volume 6, Number 1. 
 
 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 99/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
15 APPENDICES 
Appendix  1  PORTICO PK substudy  
1 STUDY OBJECTIVES 
This substudy aims to assess the pharmacokinetics ( PK) of maci tentan and its metabolite 
ACT -132577 in patients with portopulmonary hypertension from the PORTICO study.  
2 INVESTIGATIONAL PLAN 
2.1 Overall study design and plan 
This PORTICO PK substudy is a prospective, multicenter, open -label, single -arm study  
includi ng at least 20 patients  that are on steady -state treatment with macitentan in  the 
open- label period of the AC -055- 404/PORTICO study. The substudy will be conducted 
in consenting patients from all centers who agree to participate and in all regions .  
The st udy will consist of the following periods: 
• Screening period: 
A Screening visit will be scheduled within 28 days before enrollment  into the PK 
substudy . At this visit the study will be discussed with the patient and the Informed 
Consent Form will be signed. 
• PK assessments period:  
PK assessments will be performed after open -label study treatment for the  
AC-055- 404/PORTICO study has been taken for at least 4 weeks. The substudy may be 
performed on or at any time between the scheduled Visit 6 and Visit 7 of th e 
OL treatment period. The PORTICO PK substudy will consist of two visits (Day 1 and 
Day 2). On the first study day of the PORTICO PK substudy (Day 1), eligibility will be 
checked before start of assessments. Following t he check, a pre -dose blood sample wi ll 
be drawn (preferably before 10.00 am). 
On Day 1, the study treatment, one 10 mg tablet of macitentan, will be taken directly 
after the morning pre -dose blood sample. Following this, the patient will be considered 
enrolled into the PORTICO PK substudy. Blood samples for PK will then be drawn at 
specified time points after study treatment administration over a 24 -hour time period as 
presented in Figure 2. In order to ensure timely blood sampling, patients may be of fered 
an overnight stay at the clinic  or sampling may be performed local to the patient’ s home . 
The last PK blood sample will be drawn 24 hours after study treatment intake on Day 1. 
Study treatment intake on Day 2 must only occur after this last blood draw, which 
concludes the PORTICO PK substudy.  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 100/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Figure 2 PK substudy design  
 
2.2 Study population  
2.2.1 Patient population 
The patient population will consist of patients who are participating in the open- label 
period of the AC -055-404/PORTICO study and have received the  open -label  study 
treatment  (10 mg of macitentan, once daily oral dose) for at least 4 weeks. 
2.2.2 Inclusion criteria  
• Signed  Informed Consent F orm prior to initiation of any study -mandated procedure.  
• Patients particip ating in the open- label period of the AC -055- 404/PORTICO study 
and having received the open- label  study treatment for at least 4 weeks.  
• Pre-dose PK blood sampling done prior to study medication on Day 1. 
2.2.3 Exclusion criteria  
• Clinical instability during  the week prior to enrollment into the substudy. 
• Ongoing renal failure or dialysis. 
• Arm veins unsuitable for i.v. puncture. 
2.2.4 Concomitant medications  
All other concomitant medications are allowed, but must be kept stable for at least one 
week prior to enrollment on Day 1 and during the 24 hours of PK sampling. 
2.2.4.1 Prohibited concomitant medications  
All prohibited concomitant medications are listed in Section 5.2.4 of the 
AC-055-404/PORTICO study protocol. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 101/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
2.3 Study treat ment  
The study treatment is macitentan, 10 mg provided for the AC-055-404/PORTICO study.  
2.3.1 Treatment dose and administration 
Patients can only be enrolled if the study treatment for the AC -055- 404/PORTICO study 
was continuously taken for at least 4 weeks during the open -label period. On Day 1 of the 
PORTICO PK substudy, the study treatment will be taken directly after the pre-dose 
blood sample. On Day 2 study treatment will be taken after the last (24  h) PK blood 
sample was drawn. If the study treatmen t intake during the PK sampling days is  
performed at the clinic, patients must bring at least two tablets when visiting the site on 
Day 1. The study treatment  intake on Day 1 and Day 2 must be observed by the 
investigator / study coordinator  / phlebotomist  and the date and exact times will be 
recorded in the electronic Case Report Form (eCRF) . 
2.3.2 Pharmacokinetic and pharmacodynamic endpoints  
Plasma PK variables  of ACT -132577 and metabolites will be derived by 
noncompartmental analysis of the plasma conce ntration -time profiles.  
PK endpoints for both macitentan and ACT -132577:  
• The area under the plasma concentration -time curve during one dosing interval 
(AUC τ). 
• Maximum plasma concentration (C max) during a dosing interval. 
• The time to reach maximum plasma concentration (t max) during a dosing interval. 
2.3.2.1 Calculation of PK endpoints and assumptions 
The PK endpoints will be derived as follows: 
• The measured individual plasma concentrations of macitentan and its metabolite, 
ACT -132577 will be used to directly obtain C max and t max. 
• AUC τ will be calculated according to the linear trapezoidal rule using the measured 
concentration -time values above the limit of quantification (LOQ) during one dosing 
interval.  
• The PK variables  will be calculated on the basis of the real (actual) blood sampl ing 
time points.  
All areas under plasma concentration -time curves (AUC) and C max values are assumed to 
be log -normally distributed. Depending on the data obtained compartmental models may 
be used. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 102/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
2.4 Study assessments 
2.4.1 Pharmacokinetic and pharmacody namic assessments  
2.4.1.1 Timing for sampling  
If applicable, p atients should arrive at the clinic on Day 1 so that the pre -dose sample can 
be drawn before 10.00 a.m. 
For the PK assessment the blood samples must be drawn at the following time points: Day 1:  Immediately before administration of the  dose of  study treatment  in the morning 
(pre-dose) and 1 h, 3 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 12 h, and 14 h post-dose. 
Day 2: 24 h post-dose. 2.4.1.2 Procedures for sampling 
Approximately 2 mL of blood will be collected in tubes containing ethylene diamine K3 
tetra-acetic acid via an i.v. catheter placed in an antecubital vein in the arm. The 
indwelling catheter will be kept patent (e.g. by insertion of a mandrin), which will be changed after each blood sampling. Immediately following collection of the required 
blood volume, the tubes will be slowly tilted backwards and forwards (no shaking) to bring the anti-coagulant into solution, and immediately cooled on ice.  
Within 30 minutes of collection, the tubes will be  centrifuged at approximately 1 500 × g 
for 10  minutes at 2 –8 °C. When a centrifuge that can be cooled is not available, the blood 
samples and the bucket of the centrifuge must be cooled on ice prior to centrifugation. 
Following centrifugation, the plasma w ill be transferred into one labeled polypropylene 
tube. All samples will be stored in an upright position at − 20 °C. The date and exact 
actual clock time of each blood sample draw will be entered into the eCRF.  
2.4.1.3 Labeling 
The tubes and labels for the  samples will be provided to the investigator and/or site staff. 
The labeling will comply with the applicable laws and regulations of the countries in 
which this substudy is conducted. 
2.4.1.4 Bioanalysis 
The concentrations of macitentan and its metabolite  ACT -132577 in plasma will be 
determined using a validated liquid chromatography coupled to mass spectrometry 
method. The foreseen LOQ in plasma for macitentan and ACT -132577 is 1 ng/mL. The 
concentrations will be calculated by interpolation from the calib ration curve. Quality 
control samples will be analyzed throughout the study. Their measured concentrations will be used to determine between -run and overall precision and accuracy of the analysis. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 103/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
2.4.1.5 Shipping procedures 
The investigator and/or site staff are responsible for shipment of the samples. Samples 
must be sent from the site to the central laboratory  using an appropriate courier service at time intervals specified in laboratory guidelines. The central laboratory will organize the shipment of PK plasma samples to  at Actelion 
Pharmaceuticals Ltd  at time intervals agreed with the 
sponsor. The plasma samples must be temperature controlled, tracked and packed  
securely with the completed shipment forms in polystyrene -insulated shipping containers 
together with enough dry ice to last for 48 hours. 
2.4.1.6 Total blood volume 
The total blood volume to be taken for the PK assessments will be approximately 
12 × 2 mL  = 24 mL  
2.5 Assessment schedule 
Figure 2 provides an overview of the chronological sequence of the assessments. 
3 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
For a detailed description of the safety definitions and reporting requirements, refer to Section 10 of the AC-055-404/PORTICO protocol. 
All AEs occurring from screening period to the 24- hour time point (Day 2) will be 
reported as AEs in the AC -055- 404/PORTICO CRF and will be analyzed and reported in 
the context of the AC-055-404/PORTICO study. 
4 STATISTICAL METHODOLOGY AND ANALYSES 
4.1 Statistical Analysis Plan 
A SAP will be written and finalized before database closure. The SAP will provide full 
details of the analyses (includin g PK), data displays, and algorithms to be used for data 
derivations.  
The SAP will include the definition of major and minor protocol deviations and the link 
between major protocol deviations and the analysis sets.  
Major and minor protocol deviations will be identified by medically trained staff before 
study closure.  

Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 104/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
4.2 Analysis sets 
The PK analysis will be performed on the PK set.  
This analysis set comprises all patients who did not deviate from the protocol in a way 
that might affect the evaluation o f the PK endpoints. 
4.3 Pharmacokinetic analysis 
4.3.1 Pharmacokinetic  statistical analysis and endpoint display 
Individual plasma concentration- time data will be listed by patient. The individual and 
mean plasma concentration -time profiles will be plotted  on a linear scale.  
The derived PK variables for macitentan and ACT -132577 (AUC τ, Cmax, and t max) will be 
listed by patient.  
For mean value calculations, all values below the LOQ (below the limit of quantification [BLQ] values) will be set to zero if ≤ 50 % of the values at a given time point are BLQ. If 
> 50% of the values at a given time point are BLQ, no mean value will be calculated. Mean concentration -time profiles will be generated using these criteria.  
Plasma concentrations per time  point will be sum marized using arithmetic mean, 
minimum, median, maximum, standard deviation ( SD), standard error ( SE), and 
two-sided 95% confidence interval of the mean.  
AUC
τ, Cmax, tmax * will be summarized with arithmetic mean, geometric mean, minimum, 
median, maximum, SD, SE, CVb in %, and 95% confidence interval  of the arithmetic and 
geometric means.  
(* For t max the geometric mean and its 95% confidence interval  will not be calculated).  
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 105/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
 
Appendix  2 C hild-Pugh, MELD , and hepatic encephalopathy scales  in 
classification of liver disease  
1) Child- Pugh Classification  
The Child -Pugh  classification  will be used for assessing  the severity  of the liver 
disease according to the following criteria:  
Score  Bilirubin  
 (mg/dL)  Albumin  
 (g/dL)  Prothrombin 
time 
 (sec prolonged)  Ascites  
 (grade)  Encephalopathy  
 (grade)  
1 < 2 > 3.5  < 4 Absent  None  
2 2–3 2.8–3.5 4–6 Slight  1–2 
3 > 3 < 2.8 > 6 Moderate 3–4 
Child -Pugh  class:  A (m ild): 5–6; B (m oderate):  7–9; C (severe):  ≥ 10 
2) MELD Score  
The MELD  score is calculated using the following formula:  
MELD Score = 0.957 × Loge(creatinine mg/dL) + 0.378 × Loge(bilirubin mg/dL) + 
1.120 × Loge(INR) + 0.6431  
Multiply the score by 10 and round to the nearest whole number.  
• Laboratory values less than 1.0 are set to 1.0 for the purposes of the MELD score 
calculation. The maximum serum creatinine considered within the MELD score equation is 4.0 mg/dL.  
• If subject h ad dialysis twice  within a week  prior to the s erum creatinine test then the 
MELD score will be calculated with a serum creatinine value of 4.0 mg/dL.  
3) Hepatic encephalopathy grades  are defined  in the table below.  
 
Grade  0 Normal consciousness, personality, neurological examination, electroencephalogram  
Grade  1 Restless, sleep disturbed, irritable/ agitated, tremor, impaired handwriting, 5 cps 
waves 
Grade  2 Lethargic, time -disoriented, inappropriate, asterixis, ataxia, slow triphasic waves  
Grade  3 Somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves  
Grade  4 Unrousa ble coma, no personality/behavior, decerebrated, slow 2 –3 cps delta activity  
 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 106/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Appendix  3 Actelion guidelines for 6MWT  
The American Thoracic Society (ATS) published an official statement on the 6- minute 
walk test ( 6MWT) in 2002 [ ATS Statement 2002]. Only a brief summary of these 
guidelines is included here. 
• The 6MWT should be performed indoors, along a long, flat, straight, enclosed 
corridor with a hard surface that is seldom traveled. The use of treadmill is forbidden. 
• The walking distance used for the test should be 30 meters (100 feet) in length. This distance should be marked every 3 meters (10 feet). The turnaround point should be marked with a cone. A starting line, which marks the  beginning and the end of each 
60-meter lap, should be marked on the floor using brightly colored tape. Any 
deviation from this should be approved in written form by Actelion before implementation.  
• The study staff member administering the 6MWT should stand near the starting line 
during the test and must not walk with the patient! Intermittent rest periods are allowed if the patient can no longer continue. If the patient needs to rest, he/she may pause, lean against the wall or sit and should continue walking whenever he/she feels able. The timer must continue to run. The test can be stopped at any moment in case the patient complains of having chest pain, intolerable dyspnea, leg cramps, or has a pale or ashen appearance.  
• The 6MWT is a non- encouraged test. No instructions or encouragement will be given 
during the test. Eye contact and body language signaling the patient to speed up should be avoided during the test. 
• For an individual patient, repeat testing should always be conducted, if possible, by 
the same tester, at the same location, and preferably at about the same time of the day 
to minimize variability.  
Required equipment:  
• Countdown timer (or stop watch) 
• Mechanical lap counter  
• Two small cones for the turnaround points 
• A chair that can be easily moved along the walking course 
• Worksheets on a clipboard 
• Sphygmomanometer 
• Automated electronic defibrillator  
• Source of oxygen 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 107/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Patient preparation  
• The patient should wear comfortable clothing and appropriate walking shoes. 
• The meals preceding the test should be light, and the patient should not have 
exercised vigorously within 2 hours of beginning the test. 
• The patient should sit at rest for at least 10 minutes before the test starts.  
• Patients should receive their usual medication on the day of the test. If the pat ient is 
used to taking bronchodilators before a walk, he/she should take them 5– 30 minutes 
before the test.  
• For patients receiving continuous 24- hour oxygen therapy, it is recommended that the 
flow rate remains constant for the duration of the study. However, from one hour prior to and until the completion of the 6MWT, the flow rate must remain constant. 
Measurement of the 6MWD/6MWT – Instructions to the patient  
The person administering the test will use the following exact dialogue with the patient: “The o bject of this test is to walk as far as possible for 6 minutes. You will walk back and 
forth in this hallway. Six minutes is a long time to walk, so you will be exerting yourself. You will probably get out of breath or become exhausted. You are permitted to slow down, to stop, and to rest as necessary. You may lean against the wall while resting, but resume walking as soon as you are able to. You will be walking back and forth around the cones. You should pivot briskly around the cones and continue back the  other way 
without hesitation. Now I ’m going to show you. Please watch the way I turn without 
hesitation ”. 
(The tester demonstrates the walking and pivots around a cone briskly). 
“Are you ready to do that? I am going to use this counter to keep track of the number of 
laps you complete. I will click it each time you turn around at this starting line. 
Remember the object is to walk AS FAR AS POSSIBLE for 6 minutes, but don’ t run or 
jog. I will tell you when 2 minutes, 4 minutes have elapsed. Keep walking when I talk. ” 
After these instructions are given to the patient, the person administering the test will then ask: 
“Do you have any questions about the test?” “Please explain what you are going to do. ” 
“Are you ready? ” 
“Start now, or whenever you are ready.” 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 108/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
As soon as the patient starts to walk, the tester will start the timer and write down start 
time.  
The tester will tell the patient the time elapsed by saying:  
“You have 4 minutes to go.” 
“You have 2 minutes to go.” When the timer is 15 seconds from completion, the tester says:  
“In a moment I ’m going to tell you to stop. When I do, just stop right where you are and I 
will come to you ”. 
When the timer alarm rings the tester says:  
“Stop!” 
The tester walks over to the patient, marks the spot where the patient sto pped, records the 
total distance walked in the worksheet and congratulates the patient on good effort. 
 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 109/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Appendix  4 Borg dyspnea index 
Borg rating  Perceived exertion  
0 
0.5 
1 
2 
3 4 5 6 7 
8 
9 10 Nothing at all  
Very, very slight (ju st noticeable)  
Very slight  
Slight (light)  
Moderate  
Somewhat severe  
Severe (heavy)  
 Very severe  
  Very, very severe (maximal)  
 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 110/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Appendix  5 WHO functional classification of pulmonary hypertension 
Class I  Patients with pulmonary hyp ertension but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue dyspnea 
of fatigue, chest pain or near syncope.  
Class II  Patients with pulmonary hypertension resulting in slight limitation of 
physical activ ity. They are comfortable at rest. Ordinary physical activity 
causes undue dyspnea or fatigue, chest pain or near syncope.  
Class III  Patients with pulmonary hypertension resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.  
Class IV  Patients with pulmonary hypertension with inability to carry out any 
physical activity without symptoms. These patients manifest signs of right 
heart failure. Dyspnea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity.  
 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 111/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Appendix  6 Laboratory abnormalities 
 
Labo ratory abnorma lities according to the most u pdated ver sion of CTC AE. A ma rked 
abnorma lity is defined based on the following list (SI units ). 
 
 
  
Parame ter  
LL  
LLL   
HH  
HHH  
HHHH 
 
 
 
Hem oglobin (g/L)  
 
 
< 100  
 
 
< 80  
Increase in 
(> 20 g/L above 
ULN) or above 
baseline if base line 
is above ULN Increase in 
(> 40 g/ L 
above ULN) or 
above base line 
if base line is 
above ULN  
 
 
 
Hematocr it < 28% 
for 
females 
< 32% 
for 
males  
 
 
< 20%   
 
 
> 60%  in men 
> 55%  in women  
 
 
> 65%   
Platelet count 
(109 /L)  
< 75  
< 25  
> 600  
> 999  
Leucocytes 
(× 109 /L)  
< 3.0  
< 2.0  
> 20.0  
> 100.0  
Neutrophils 
(109 /L)  
< 1.5  
< 1.0  
NA  
NA  
 
Eosinoph ils   > 5.0 ×  10e9 
or > 5%   
NA  
Lymphocyte 
(109 /L)  
< 0.8  
< 0.5  
> 4.0  
> 20.0  
 
AST ( U/L)  
NA  
NA  
≥ 3 × ULN   
≥ 5 × ULN   
≥ 8 × ULN  
 
ALT ( U/L)  
NA  
NA  
≥ 3 × ULN   
≥ 5 × ULN   
≥ 8 × ULN  
 
AP  
NA  
NA  
≥ 2.5 × ULN   
≥ 5 × ULN   
Total bilirubin 
(umol/L)  
NA  
NA  
≥ 2.5 × ULN   
≥ 5 × ULN   
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 112/115 Confidential  EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
  
 
Parame ter  
LL  
LLL   
HH  
HHH  
HHHH 
 
 
 
INR    
≥ 1.5 × UL N or 
> 1.5 tim es above 
baseline if on 
anticoagula tion ≥ 2.5 ×  ULN 
or 
> 2.5 tim es 
above base line if  
on 
anticoagula tion  
 
Creatinine  
(umol/L)  
NA  
NA  
≥ 1.5 × UL N or 
1.5 × base line  
≥ 3 × ULN  
or 
> 3 × base line  
Glucose 
(mm ol / L)  
< 3.0  
< 2.2  
> 8.9  
> 13.9  
Calcium ( mmol/L) < 2.0 < 1.75 > 2.9 > 3.1  
 
Sodium (mm ol/L)   
< 130  
> 150  
> 155  
Potassium 
(mm ol/L)  
< 3.2  
< 3.0  
> 5.5  
> 6.0  
Magnesium 
(mm ol/L)  
< 0.5  
< 0.4  
-  
> 1.23  
Uric acid 
(mm ol/L)  
-  
-  
> 0.59  
> 0.72  
 
Album in (g/L)   
< 30  
< 20  
-  
-  
 
BUN  
-  
-  
≥ 2.5 × ULN  
≥ 5 × ULN  
ALT  = alanine ami notransferase; AP = alkaline phosphatase; AST = asparta te ami notransferase;  
BUN = blood ure a nitrogen; CTCAE = common termi nology criteria for ad verse events; LL / HH = marked 
abnorma lities ; LLL / HHH / HHHH = alert values; INR = interna tional norma lized ra tio; NA = not 
applicable; SI = interna tional sy stem of unit; U LN = upper limit of th e normal ran ge. 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 113/115 Confidenti al EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Appendix  7 Cen tral laboratory al ert flags 
On top of the fl ags described below, at a minimum, resul ts above the upper limit or 
below the low er limit of the refer ence range f or norm al subjec ts will be fl agged. 
•  Exclusionary Alert Value - At Scr eening (V1): The result is outside the study 
specifi c defi ned limit for inclusion in the st udy. 
− Hemoglobin < 100 g/ L  
− AST ≥ 3 × ULN  
− ALT ≥ 3 × U LN 
− Bilirubin ≥  3 mg/dL  
− Serum pr egnan cy test positive 
•  Total Bilir ubin  flag Alert Value - A ll visits ex cept scr eening (V1):  
In co mbi nation wi th ALT and/or AST ≥  3 × ULN 
− Total bilirubin ≥ 2 × U LN 
Dependent on  previous total bilirubin assessment, stopping study treatment  should be 
considered (i.e., worsening). 
• Interrupt ion or permanent d iscontinuation of study treatment  - All visits excep t 
screening (V1): 
Please r efer to the s tudy protocol; study treatment must be inte rrupted [see protocol  
Section 5.1.11]: 
− Asymptomatic increase ALT and/or AST ≥  3 and < 8 × ULN  
Study treatment  must be permanently stopped in case of: 
− Aminotransferases ≥ 8 × ULN  
− Aminotransferases ≥ 3 × ULN and associated with new or worsening 
clinical symptoms of liver injury, e.g., nausea, vomiting, fever, abdominal 
pain, jaundice, unusual lethargy or fatigue, flu like syndrome (arthralgia, myalgia, fever)  
− Aminotransferases ≥ 3 × ULN and associated with total bilirubin 
≥ 2 × ULN and increased as compared to baseline  
− Serum pr egnan cy test positive 
− Hemoglobin < 80 g/L  
− Hemoglobin > 50 g/L  decrease from base line 
•  Repeat Alert value - Al l visits aft er random ization (V2): 
Repea t testing is nee ded:  
− AST ≥ 3 × ULN  
− ALT ≥ 3 × U LN 
− Hemoglobin > 20 g/L  decrease from base line 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 114/115 Confidenti al EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Appendix 8 List of protocol amendments 
Document 
Date  Amendment  Changes  
15 JAN 2015 Amendment 1, 
resulting in Global 
Protocol Version 2  • Visit window was changed to ± 4 days from ±  7 days to 
ensure patients ha d enough study treatment until the next 
visit.  
• Refe rence to hepatic event questionnaire was removed 
as this form was removed from the eCRF  
• Daclatasvir was added as permitted Hepatitis C 
medication following its approval 
• Analysis of urea  was removed as it was not needed in 
addition to blood urea nitrogen. 
• NT-proBNP storage/shipping text was further clarified  
• It was clarified that laboratory assessments to be used for eligibility assessment were those performed at Visit  1 / Screening (not Visit 2 / Randomization). 
• A urine dipstick pregnancy test was added to the 
assessments at Visit  2 / Randomization in order to have 
the result prior to treatment assignment.  
• It was clarified that HVC was not mandatory  
• It was clarified that PAH or PoPH medications stopped within 3  months prior to randomization were required to 
be documented in the eCRF.  
9 JUN 2015  Local Amendment, 
resulting in Local protocol version 
2.FRA.A • An OLE period was added to the study in order to ensure 
that patients continued receiving study treatment after study completion (i.e., including the OL per iod) 
 
5 AUG 2015  Local Amendment 
resulting in Local 
protocol version 
2.GBR.A • Inclusion was restricted to WHO FC III –IV, in order to 
enroll only patients for whom the local commissioning 
guidelines would permit continued macitentan treatment after study co mpletion.
 
21 A PR 2016  Amendment 2, 
resulting in Global 
Protocol Version 3 
and Local protocol 
version 3.GBR.A  • It was clarified that  local laboratory assessments were 
allowed in order to simplify eligibility assessment and 
implementation of the stopping rule (i.e., for calculating 
MELD score and/or Child -Pugh classification) at Week 
12. It was further clarified that the central laboratory kit 
was required to be used in parallel to the use of local 
laboratory assessments.  
• It was clarified that study treatme nt was allowed to be 
continued in case of OLT during the OL period of the 
Macitentan / ACT -064992  
Portopulmonary hypertension  
Protocol AC -055-404 
Version 3  
21 April 2016, page 115/115 Confidenti al EudraCT 2014 -004624 -21 
Doc No D- 16.102  
 
Document 
Date  Amendment  Changes  
study, based on medical consideration.  
• It was allowed to perform the PK substudy closer to the 
patient’s home to ease participation  
• Certain eligibility criteria were modified based o n 
medical considerations, e.g., exclusion criterion 15: transplant expected within 3 months removed; exclusion 
21: CCBs moved to exclusion 20; beta blockers moved 
to exclusion 10) 
• The list of allowed and forbidden medicat ions was 
updated with newly approved antiviral medications 
• It was clarified that screening started on the day of ICF 
signature  
• The definition of the Full Analysis Set was modified to 
include patients for whom post -baseline PVR was 
imputed. 
21 A PR 2016  Local Amendment, 
resulting in Local protocol version 
3.FRA.B  • It was also allowed to perform the PK substudy during 
the OLE as the requirement to have been on OL 
treatment for 4  weeks is met during the OLE.   
 
CCB = calcium channel blocker; eCRF   = electronic Case Report Form; FC = functional class; HVC = hepatic vein 
catheterization ; ICF = informed consent form; MELD = Model for End-Stage Liver Disease; NT-proBNP = N-
terminal pro -brain natriuretic peptide; OL = open-label; OLE = open-label extension; OLT = orthotopic liver 
transplantation ; PAH = pulmonary arterial hypertension; PoPH = portopulmonary hypertension; PK = 
pharmacokinetic; PVR = pulmonary vascular resistance; WHO = World Health Organization.  
 